# Rewrite chunk 006 — entries 251-300

_Previous: rewrite-PHONE-005.md | Next: rewrite-PHONE-007.md | Index: rewrite-PHONE-INDEX.md_

Edit ONLY the `YOUR REWRITE` section under each entry. The `Original`
block is frozen — do not edit it. Save the file when done. On your
laptop run `python C:\E156\merge-rewrite.py` to assemble a new
workbook (`rewrite-workbook.NEW.txt`) with your edits applied.

---

## Entry 251 ([257/921]) — ipd_qma_project

<details><summary>Metadata</summary>

```
TITLE: IPD-QMA: Quantile Meta-Analysis for Detecting Heterogeneous Treatment Effects Across Patient Severity
TYPE: methods  |  ESTIMAND: Quantile-specific treatment effect with bootstrap CI
DATA: Simulated and real IPD datasets with severity-varying treatment response
PATH: C:\Projects\ipd_qma_project
```

</details>

### Original (frozen — do not edit)

```
Can quantile-based meta-analysis detect heterogeneous treatment effects across patient severity distributions that mean-based pooling would mask? We developed IPD-QMA as a Python package implementing quantile regression meta-analysis with bootstrap inference for individual participant data across multiple trials. The method estimates treatment effects at each decile of the baseline severity distribution, tests for quantile-treatment interaction, and visualises effect heterogeneity across the severity continuum with pointwise and simultaneous confidence bands. In simulation studies with known heterogeneous effects the quantile interaction test achieved power of 0.87 (95% CI 0.83 to 0.91) at the 5 percent significance level, compared with 0.34 for the standard mean interaction test under the same conditions. Applied to a clinical dataset the method revealed that treatment benefit concentrated in the upper severity quartile while the lower quartile showed near-null effects. Quantile meta-analysis could identify patient subgroups with differential treatment response that averaged pooling obscures. The method requires IPD availability and statistical power decreases substantially in the distribution tails where sample sizes are smallest.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can quantile-based meta-analysis detect heterogeneous treatment effects across patient severity distributions that mean-based pooling would mask? We developed IPD-QMA as a Python package implementing quantile regression meta-analysis with bootstrap inference for individual participant data across multiple trials. The method estimates treatment effects at each severity decile, tests for quantile-treatment interaction, and visualises effect heterogeneity with pointwise and simultaneous confidence bands. In simulation studies the quantile interaction test achieved power of 0.87 (95% CI 0.83 to 0.91) at the 5 percent level, compared with 0.34 for the standard mean interaction test. Applied to a clinical dataset the method revealed treatment benefit concentrated in the upper severity quartile while the lower quartile showed near-null effects. Quantile meta-analysis could identify patient subgroups with differential treatment response that averaged pooling obscures. The method requires IPD availability and statistical power decreases in distribution tails where sample sizes are smallest.
<!-- END-REWRITE -->

_Line range 18945-19020 in rewrite-workbook.txt_

---

## Entry 252 ([258/921]) — IPDSimulator

<details><summary>Metadata</summary>

```
TITLE: IPD Simulator: Browser-Based Reconstruction of Individual Participant Data from Published Summaries
TYPE: methods  |  ESTIMAND: Reconstruction accuracy (KS statistic vs original IPD)
DATA: Published Kaplan-Meier curves, binary 2x2 tables, and continuous summary statistics
PATH: C:\Models\IPDSimulator
```

</details>

### Original (frozen — do not edit)

```
Can individual participant data be reliably reconstructed from published aggregate summaries in a browser without requiring R or specialised statistical software? We built IPD Simulator as a 1,373-line single-file application implementing Guyot algorithm reconstruction from Kaplan-Meier curves, exact binary data recreation from two-by-two tables, and parametric distribution fitting for continuous outcomes. The tool accepts digitised survival coordinates with number-at-risk tables, binary event counts, or continuous means with standard deviations and sample sizes to generate downloadable IPD datasets. Reconstructed survival data achieved Kolmogorov-Smirnov statistics below 0.05 against original published curves across all validation datasets, indicating excellent distributional agreement. For binary outcomes the reconstruction was exact, and continuous reconstruction maintained mean and variance within rounding tolerance of input summaries. Browser-based IPD reconstruction could enable researchers to perform advanced patient-level analyses when data sharing agreements are impractical. The Guyot algorithm assumes piecewise constant hazards between reported time points and accuracy degrades with fewer number-at-risk reporting intervals.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can individual participant data be reconstructed from published summaries in a browser without requiring R or specialised software? We built IPD Simulator as a 1,373-line application implementing Guyot algorithm reconstruction from Kaplan-Meier curves, exact binary data recreation from two-by-two tables, and parametric distribution fitting for continuous outcomes. The tool accepts digitised survival coordinates with number-at-risk tables, binary event counts, or means with standard deviations to generate downloadable IPD datasets. Reconstructed survival data achieved Kolmogorov-Smirnov statistics below 0.05 against original curves across all validation datasets, indicating excellent distributional agreement. For binary outcomes reconstruction was exact; continuous reconstruction maintained mean and variance within rounding tolerance of input summaries. Browser-based IPD reconstruction could enable researchers to perform patient-level analyses when data sharing agreements prove infeasible. The Guyot algorithm assumes piecewise constant hazards and accuracy degrades with fewer number-at-risk reporting intervals.
<!-- END-REWRITE -->

_Line range 19021-19097 in rewrite-workbook.txt_

---

## Entry 253 ([259/921]) — KMextract

<details><summary>Metadata</summary>

```
TITLE: KMextract: Automated Kaplan-Meier Curve Digitisation and Data Extraction
TYPE: methods  |  ESTIMAND: Digitisation accuracy (mean absolute error vs original coordinates)
DATA: Published Kaplan-Meier survival curve images from clinical trials
PATH: C:\KMextract
```

</details>

### Original (frozen — do not edit)

```
Can automated digitisation of Kaplan-Meier survival curves produce coordinate data accurate enough for IPD reconstruction without manual point-by-point tracing? We developed KMextract implementing image processing algorithms for axis detection, curve tracing, and coordinate extraction from published Kaplan-Meier plot images. The tool applies edge detection, colour segmentation, and spline interpolation to automatically identify survival curves, time axes, and probability axes from standard publication-format survival plots. Across a validation set of published cardiovascular trial curves the automated extraction achieved mean absolute error of 0.012 (95% CI 0.008 to 0.016) in survival probability compared with manually digitised reference coordinates. Automatic axis detection correctly identified time ranges and probability scales in 94 percent of test images without manual calibration. Automated curve digitisation could reduce the bottleneck of manual data extraction in meta-analyses of time-to-event outcomes where only Kaplan-Meier figures are available. The tool requires clear image resolution and cannot handle overlapping curves or non-standard plot formatting without manual intervention.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can automated digitisation of Kaplan-Meier curves produce coordinates accurate enough for IPD reconstruction without manual tracing? We developed KMextract implementing image processing for axis detection, curve tracing, and coordinate extraction from published Kaplan-Meier images. The tool applies edge detection, colour segmentation, and spline interpolation to identify survival curves, time axes, and probability axes from standard publication-format plots. Across validation cardiovascular trial curves the automated extraction achieved mean absolute error of 0.012 (95% CI 0.008 to 0.016) in survival probability compared with manually digitised reference coordinates. Automatic axis detection correctly identified time ranges and probability scales in 94 percent of test images without manual calibration. Automated curve digitisation could reduce the bottleneck in meta-analyses of time-to-event outcomes where only Kaplan-Meier figures are available. The tool requires clear image resolution and cannot handle overlapping curves or non-standard plot formatting without manual intervention.
<!-- END-REWRITE -->

_Line range 19098-19173 in rewrite-workbook.txt_

---

## Entry 254 ([260/921]) — lec_phase0_bundle

<details><summary>Metadata</summary>

```
TITLE: LEC Phase 0 Bundle: London Evidence Clinic Reproducibility Package
TYPE: methods  |  ESTIMAND: Bundle completeness and reproducibility score
DATA: Clinical evidence synthesis outputs bundled for reproducibility audit
PATH: C:\Projects\lec_phase0_bundle
```

</details>

### Original (frozen — do not edit)

```
Can a structured reproducibility bundle package clinical evidence synthesis outputs into a self-contained auditable archive that enables independent verification without re-running the analysis? We assembled the London Evidence Clinic phase zero bundle containing analysis scripts, input datasets, output tables, forest plots, configuration files, and validation checksums in a standardised directory structure. The bundle follows the TruthCert packaging standard requiring manifest files listing all contents with cryptographic hashes, dependency declarations, and execution instructions for reproducing each output from raw inputs. All 26 bundled files passed integrity verification with SHA-256 hash matching against the manifest, confirming no post-generation modification of analysis outputs. Execution of the bundled scripts reproduced all numerical outputs within machine epsilon of the archived results on a clean test environment. Structured reproducibility bundles could become a standard submission supplement enabling reviewers to verify numerical claims without requesting original datasets or software environments. The bundle preserves computational outputs and cannot guarantee that the underlying clinical data or patient records meet regulatory requirements for secondary use.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a reproducibility bundle package evidence synthesis outputs into a self-contained auditable archive enabling independent verification? We assembled the London Evidence Clinic phase zero bundle containing analysis scripts, input datasets, output tables, forest plots, configuration files, and validation checksums in a standardised directory structure. The bundle follows TruthCert packaging requiring manifest files with cryptographic hashes, dependency declarations, and execution instructions for reproducing each output from raw inputs. All 26 bundled files passed integrity verification with SHA-256 hash matching against the manifest, confirming no post-generation modification. Execution of bundled scripts reproduced all numerical outputs within machine epsilon of archived results on a clean test environment. Structured reproducibility bundles could become a standard submission supplement enabling reviewers to verify numerical claims. The bundle preserves computational outputs and cannot guarantee that underlying clinical data meets regulatory requirements for secondary use.
<!-- END-REWRITE -->

_Line range 19174-19249 in rewrite-workbook.txt_

---

## Entry 255 ([261/921]) — lec_phase0_project

<details><summary>Metadata</summary>

```
TITLE: LEC Phase 0 Project: London Evidence Clinic Initial Evidence Synthesis Infrastructure
TYPE: methods  |  ESTIMAND: Infrastructure readiness and pipeline validation pass rate
DATA: Evidence synthesis pipeline components with validation test suites
PATH: C:\Projects\lec_phase0_project
```

</details>

### Original (frozen — do not edit)

```
Can a modular evidence synthesis infrastructure be validated to clinical-grade standards before deploying it for patient-facing evidence summaries in a cardiology clinic setting? We developed the London Evidence Clinic phase zero project establishing the foundational pipeline for automated evidence retrieval, screening, extraction, meta-analysis, and summary generation for cardiovascular clinical questions. The infrastructure implements PubMed API integration, title-abstract screening classifiers, structured data extraction templates, random-effects meta-analysis, and GRADE certainty assessment in a reproducible pipeline with 28 component modules. All 28 pipeline modules passed unit validation with zero failures, and end-to-end integration testing reproduced reference meta-analysis results within numerical tolerance for three cardiovascular benchmark questions. Security audit confirmed no credential exposure, API key storage follows environment variable isolation, and patient data handling pathways were validated against GDPR requirements. Clinical-grade evidence synthesis infrastructure could enable point-of-care evidence summaries that are continuously updated as new trial results are published. The phase zero validation covers pipeline mechanics and does not yet include clinical validation of generated evidence summaries against expert consensus.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can modular evidence synthesis infrastructure be validated to clinical-grade standards before deploying patient-facing summaries in a cardiology setting? We developed the London Evidence Clinic phase zero project establishing the pipeline for automated evidence retrieval, screening, extraction, meta-analysis, and summary generation for cardiovascular clinical questions. The infrastructure implements PubMed integration, screening classifiers, data extraction templates, random-effects meta-analysis, and GRADE certainty assessment across 28 component modules. All 28 pipeline modules passed unit validation with zero failures; end-to-end testing reproduced reference meta-analysis results within numerical tolerance for three benchmark questions. Security audit confirmed no credential exposure, API key isolation via environment variables, and patient data pathways validated against GDPR requirements. Clinical-grade infrastructure could enable point-of-care evidence summaries continuously updated as new trial results are published. Phase zero validation covers pipeline mechanics and does not include clinical validation of generated summaries against expert consensus.
<!-- END-REWRITE -->

_Line range 19250-19325 in rewrite-workbook.txt_

---

## Entry 256 ([262/921]) — LFAHFN

<details><summary>Metadata</summary>

```
TITLE: LFAHFN: Left Atrial Appendage and Heart Failure Network Analysis
TYPE: clinical  |  ESTIMAND: Pooled hazard ratio for stroke prevention outcomes
DATA: Published RCTs and observational studies on LAA closure and HF management
PATH: C:\Projects\LFAHFN
```

</details>

### Original (frozen — do not edit)

```
What is the comparative effectiveness of left atrial appendage closure strategies in heart failure patients with atrial fibrillation for stroke prevention and mortality? We conducted a network analysis of published randomised controlled trials and observational studies comparing percutaneous LAA closure devices, surgical LAA exclusion, and anticoagulation strategies in heart failure patients with concomitant atrial fibrillation. The analysis applied random-effects meta-analysis for pairwise comparisons and network meta-analysis where connected networks were available across stroke, bleeding, and mortality endpoints. Pooled analysis showed a trend toward reduced stroke with percutaneous LAA closure compared to anticoagulation alone, though confidence intervals included the null for heart failure subgroups with limited trial representation. Heterogeneity across studies was moderate, reflecting differences in heart failure severity, device generation, and anticoagulation comparators included across the evidence base. Structured comparison of LAA management strategies in heart failure could guide device selection and anticoagulation decisions in this high-risk population. The evidence base is sparse for dedicated heart failure subgroups and most device trials did not prospectively stratify by heart failure status.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What is the comparative effectiveness of left atrial appendage closure strategies in heart failure patients with atrial fibrillation? We conducted a network analysis of published trials and observational studies comparing percutaneous LAA closure, surgical exclusion, and anticoagulation in heart failure patients with concomitant atrial fibrillation. The analysis applied random-effects meta-analysis for pairwise comparisons and network meta-analysis where connected networks were available across stroke, bleeding, and mortality endpoints. Pooled analysis showed a trend toward reduced stroke with percutaneous LAA closure compared to anticoagulation alone, though confidence intervals included the null for heart failure subgroups. Heterogeneity across studies was moderate, reflecting differences in heart failure severity, device generation, and anticoagulation comparators. Structured comparison of LAA management strategies in heart failure could guide device selection and anticoagulation decisions in this high-risk population. The evidence base is sparse for heart failure subgroups and most device trials did not prospectively stratify by heart failure status.
<!-- END-REWRITE -->

_Line range 19326-19401 in rewrite-workbook.txt_

---

## Entry 257 ([263/921]) — Living metas

<details><summary>Metadata</summary>

```
TITLE: RapidMeta Cardiology: Finerenone Ultra-Precision Living Meta-Analysis Platform
TYPE: clinical  |  ESTIMAND: Pooled hazard ratio for cardiovascular and renal outcomes
DATA: Finerenone RCTs (FIDELIO-DKD, FIGARO-DKD, FINEARTS-HF) with living updates
PATH: C:\Living metas
```

</details>

### Original (frozen — do not edit)

```
Can a living meta-analysis platform provide continuously updated ultra-precision pooled estimates for finerenone cardiovascular and renal outcomes as new trial data emerge? We built a 7,473-line browser application implementing random-effects meta-analysis with Hartung-Knapp confidence intervals, Trial Sequential Analysis monitoring boundaries, GRADE certainty assessment, and fragility index computation for the finerenone evidence base. The platform integrates data from FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF with an architecture supporting automated incorporation of future trials as they report. The pooled hazard ratio for the composite cardiovascular endpoint was 0.86 (95% CI 0.78 to 0.95) with I-squared of 18 percent and fragility index of 7 across the three included trials. Trial Sequential Analysis confirmed that the cumulative Z-statistic crossed the monitoring boundary, indicating sufficient information to declare a statistically robust cardiovascular benefit. Living meta-analysis with monitoring boundaries could provide real-time evidence surveillance for emerging therapies crossing the clinical decision threshold. The platform requires manual data entry from published trial reports and cannot automatically ingest results from clinical trial registries or regulatory submissions.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a living meta-analysis platform provide continuously updated pooled estimates for finerenone cardiovascular and renal outcomes as new trial data emerge? We built a 7,473-line browser application implementing random-effects meta-analysis with Hartung-Knapp intervals, Trial Sequential Analysis monitoring, GRADE certainty assessment, and fragility computation for the finerenone evidence base. The platform integrates FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF with architecture supporting automated incorporation of future trials. The pooled hazard ratio for the composite cardiovascular endpoint was 0.86 (95% CI 0.78 to 0.95) with I-squared of 18 percent and fragility index of 7. Trial Sequential Analysis confirmed that the cumulative Z-statistic crossed the monitoring boundary indicating sufficient information to declare a statistically robust cardiovascular benefit. Living meta-analysis with monitoring boundaries could provide real-time evidence surveillance for emerging therapies. The platform requires manual data entry from published trial reports and cannot automatically ingest results from registries or regulatory submissions.
<!-- END-REWRITE -->

_Line range 19402-19477 in rewrite-workbook.txt_

---

## Entry 258 ([264/921]) — LivingMA

<details><summary>Metadata</summary>

```
TITLE: LivingMA: Living Meta-Analysis Dashboard Framework with Timeline and What-If Analysis
TYPE: methods  |  ESTIMAND: Cumulative pooled estimate with temporal change-point detection
DATA: Chronologically ordered meta-analysis study data with publication dates
PATH: C:\Models\LivingMA
```

</details>

### Original (frozen — do not edit)

```
Can a living meta-analysis dashboard combine temporal tracking, what-if scenario analysis, and change-point detection to provide dynamic evidence monitoring beyond static forest plots? We developed LivingMA as a browser-based framework implementing cumulative meta-analysis timelines, prospective Trial Sequential Analysis boundaries, what-if study addition scenarios, and automated change-point detection using CUSUM and Bayesian online change-point algorithms. The dashboard accepts chronologically ordered study data and computes cumulative pooled estimates at each study entry, monitoring whether the evidence has crossed pre-specified decision boundaries. Change-point detection correctly identified simulated evidence direction changes within two studies of the true change-point in 91 percent of test scenarios (95% CI 86 to 95). What-if analysis allowed users to model hypothetical new study additions and observe their impact on the cumulative estimate and monitoring boundaries in real time. Dynamic evidence dashboards could replace static periodic meta-analysis updates with continuous monitoring that signals when conclusions may have changed. The framework assumes studies arrive chronologically by publication date and cannot account for pre-publication data availability or reporting lag.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a living meta-analysis dashboard combine temporal tracking, what-if analysis, and change-point detection for dynamic evidence monitoring? We developed LivingMA as a browser framework implementing cumulative meta-analysis timelines, Trial Sequential Analysis boundaries, what-if study scenarios, and change-point detection using CUSUM and Bayesian online algorithms. The dashboard accepts chronologically ordered study data and computes cumulative pooled estimates at each entry, monitoring whether evidence has crossed decision boundaries. Change-point detection correctly identified simulated direction changes within two studies of the true change-point in 91 percent of test scenarios (95% CI 86 to 95). What-if analysis allowed users to model hypothetical study additions and observe impact on cumulative estimates and monitoring boundaries in real time. Dynamic evidence dashboards could replace static periodic updates with continuous monitoring that signals when conclusions may have changed. The framework assumes chronological study arrival and cannot account for pre-publication data availability or reporting lag.
<!-- END-REWRITE -->

_Line range 19478-19554 in rewrite-workbook.txt_

---

## Entry 259 ([265/921]) — LivingMeta_Watchman_Amulet

<details><summary>Metadata</summary>

```
TITLE: Watchman vs Amulet Living Meta-Analysis: Comparative Effectiveness of Left Atrial Appendage Closure Devices
TYPE: clinical  |  ESTIMAND: Pooled risk ratio for device-related complications and stroke
DATA: Published RCTs and registries comparing Watchman FLX vs Amulet LAA closure devices
PATH: C:\Projects\LivingMeta_Watchman_Amulet
```

</details>

### Original (frozen — do not edit)

```
Is the Amulet left atrial appendage closure device non-inferior to Watchman FLX for stroke prevention and device-related complications in patients with atrial fibrillation? We conducted a living meta-analysis of published randomised and observational studies comparing Watchman FLX and Amulet devices as a 3,590-line browser application with automated cumulative pooling and monitoring. The analysis applied random-effects meta-analysis with Hartung-Knapp confidence intervals for stroke, device embolisation, pericardial effusion, and residual leak endpoints. The pooled risk ratio for stroke was 0.94 (95% CI 0.72 to 1.23) favouring neither device, with I-squared of 0 percent indicating no detectable heterogeneity across included studies. Device embolisation rates were numerically lower with Watchman FLX while pericardial effusion rates were similar, though neither comparison reached statistical significance with the current evidence volume. Living meta-analysis of LAA closure devices could provide real-time monitoring as new comparative data emerge from ongoing registries and randomised trials. The evidence base consists primarily of short-term follow-up data and cannot assess comparative durability or long-term stroke prevention beyond available reporting periods.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Is the Amulet LAA closure device non-inferior to Watchman FLX for stroke prevention and complications in atrial fibrillation? We conducted a living meta-analysis comparing Watchman FLX and Amulet devices as a 3,590-line browser application with automated cumulative pooling and monitoring. The analysis applied random-effects meta-analysis with Hartung-Knapp intervals for stroke, device embolisation, pericardial effusion, and residual leak endpoints. The pooled risk ratio for stroke was 0.94 (95% CI 0.72 to 1.23) favouring neither device, with I-squared of 0 percent indicating no detectable heterogeneity. Device embolisation rates were numerically lower with Watchman FLX while pericardial effusion rates were similar, though neither reached statistical significance with current evidence volume. Living meta-analysis of LAA closure devices could provide real-time monitoring as new comparative data emerge from registries and trials. The evidence base consists primarily of short-term follow-up and cannot assess comparative durability or long-term stroke prevention.
<!-- END-REWRITE -->

_Line range 19555-19631 in rewrite-workbook.txt_

---

## Entry 260 ([266/921]) — MAConverter

<details><summary>Metadata</summary>

```
TITLE: MA Converter: Universal Effect Size Translator for Meta-Analytic Inputs
TYPE: methods  |  ESTIMAND: Converted effect size with propagated confidence interval
DATA: Effect size formulas validated against Borenstein et al. reference calculations
PATH: C:\Models\MAConverter
```

</details>

### Original (frozen — do not edit)

```
Can a universal effect size translator accurately convert between all common meta-analytic effect measures while correctly propagating uncertainty through each transformation? We built MA Converter as a 1,686-line browser application implementing bidirectional conversion between odds ratios, risk ratios, risk differences, hazard ratios, standardised mean differences, correlation coefficients, and number needed to treat. The tool applies published conversion formulas with delta-method variance propagation to produce converted effect sizes with confidence intervals that account for transformation-induced uncertainty. All conversions matched Borenstein reference calculations within four decimal places across 24 test scenarios spanning small and large effects, rare and common events, and varying sample sizes. Bidirectional round-trip conversion preserved the original estimate within numerical tolerance, confirming that the forward and inverse transformations were algebraically consistent. Universal effect size conversion could reduce errors in multi-format meta-analyses where studies report different effect measures for the same comparison. The conversion formulas assume large-sample approximations and may be inaccurate for very small samples or extreme event rates near zero or one.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a universal translator accurately convert between all common meta-analytic effect measures while correctly propagating uncertainty? We built MA Converter as a 1,686-line browser application implementing bidirectional conversion between odds ratios, risk ratios, risk differences, hazard ratios, standardised mean differences, correlation coefficients, and number needed to treat. The tool applies published conversion formulas with delta-method variance propagation to produce converted effect sizes with confidence intervals accounting for transformation uncertainty. All conversions matched Borenstein reference calculations within four decimal places across 24 test scenarios spanning small and large effects and varying sample sizes. Bidirectional round-trip conversion preserved the original estimate within numerical tolerance confirming algebraic consistency of forward and inverse transformations. Universal effect size conversion could reduce errors in multi-format meta-analyses where studies report different effect measures. The formulas assume large-sample approximations and may be inaccurate for very small samples or extreme event rates near zero or one.
<!-- END-REWRITE -->

_Line range 19632-19708 in rewrite-workbook.txt_

---

## Entry 261 ([267/921]) — MAFI

<details><summary>Metadata</summary>

```
TITLE: MAFI: Meta-Analysis Fragility Index with Eight-Signal Publication Bias Calibration
TYPE: methods  |  ESTIMAND: Calibrated publication bias probability (0-100)
DATA: Meta-analysis datasets for fragility index and bias signal computation
PATH: C:\Projects\MAFI
```

</details>

### Original (frozen — do not edit)

```
Can combining eight independent statistical signals into a calibrated probability score provide more reliable publication bias detection than any single test alone? We developed MAFI as a publication bias detection tool implementing Egger regression, Begg rank correlation, trim-and-fill, PET-PEESE, p-curve analysis, excess significance, small-study effects, and selection model testing, each contributing to a composite score from zero to one hundred. The calibration maps individual test results through validated thresholds to a unified probability scale, weighting signals by their known statistical properties and independence structure. Across validation meta-analyses the composite score achieved area under the curve of 0.89 (95% CI 0.84 to 0.93) for detecting simulated publication bias, compared with 0.74 for the best single-method approach. Sensitivity analysis confirmed that the composite score was robust to removal of any single contributing method, with AUC remaining above 0.85 in all leave-one-method-out configurations. Multi-signal bias detection could reduce both false positive accusations and missed bias in routine meta-analysis quality assessment. The composite score reflects statistical asymmetry patterns and cannot distinguish publication bias from genuine small-study effects or clinical heterogeneity.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can combining eight independent statistical signals into a calibrated probability provide more reliable publication bias detection than any single test? We developed MAFI implementing Egger regression, Begg correlation, trim-and-fill, PET-PEESE, p-curve, excess significance, small-study effects, and selection model testing into a composite score from zero to one hundred. Calibration maps individual test results through validated thresholds to a unified probability scale, weighting by known statistical properties and independence structure. The composite score achieved area under the curve of 0.89 (95% CI 0.84 to 0.93) for detecting simulated publication bias, compared with 0.74 for the best single-method approach. Sensitivity analysis confirmed robustness to removal of any single method, with AUC remaining above 0.85 in all leave-one-method-out configurations. Multi-signal bias detection could reduce both false positive accusations and missed bias in routine meta-analysis quality assessment. The composite score reflects statistical asymmetry patterns and cannot distinguish publication bias from genuine small-study effects.
<!-- END-REWRITE -->

_Line range 19709-19784 in rewrite-workbook.txt_

---

## Entry 262 ([268/921]) — MAFI-Continuation

<details><summary>Metadata</summary>

```
TITLE: MAFI Calculator Complete Edition: Fragility Analysis with GRADE Integration
TYPE: methods  |  ESTIMAND: Fragility index with GRADE-informed certainty adjustment
DATA: Meta-analysis datasets with GRADE domain assessments
PATH: C:\Projects\MAFI-Continuation
```

</details>

### Original (frozen — do not edit)

```
Can fragility index calculation be enhanced with GRADE certainty integration to provide a unified robustness assessment that combines statistical fragility with evidence quality? We extended the MAFI calculator as a 2,493-line browser application implementing fragility index computation, reverse fragility index, fragility quotient, and a novel GRADE-fragility interaction score that adjusts fragility interpretation based on evidence certainty. The tool computes how many event reassignments in the least robust study would reverse the meta-analytic conclusion, then contextualises this number against the GRADE certainty rating to produce a combined robustness assessment. Across test meta-analyses the median fragility index was 3 (IQR 1 to 7), and the GRADE-adjusted interpretation reclassified 18 percent of results from statistically robust to conditionally fragile when evidence certainty was low or very low. Reverse fragility analysis identified how many events would need to be removed to restore significance in borderline non-significant meta-analyses. Combined fragility and certainty assessment could provide a more complete picture of meta-analytic robustness than either metric alone. The GRADE-fragility interaction score uses heuristic thresholds that have not been validated against prospective outcome data.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can fragility index calculation be enhanced with GRADE certainty integration for a unified robustness assessment combining statistical fragility with evidence quality? We extended the MAFI calculator as a 2,493-line browser application implementing fragility index, reverse fragility, fragility quotient, and a novel GRADE-fragility interaction score adjusting interpretation based on evidence certainty. The tool computes how many event reassignments in the least robust study would reverse the meta-analytic conclusion, then contextualises against the GRADE rating. Across test meta-analyses the median fragility index was 3 (IQR 1 to 7); GRADE-adjusted interpretation reclassified 18 percent of results from robust to conditionally fragile when certainty was low or very low. Reverse fragility analysis identified how many events would need removal to restore significance in borderline non-significant meta-analyses. Combined fragility and certainty assessment could provide a more complete picture of robustness than either metric alone. The GRADE-fragility interaction score uses heuristic thresholds not yet validated against prospective outcome data.
<!-- END-REWRITE -->

_Line range 19785-19860 in rewrite-workbook.txt_

---

## Entry 263 ([269/921]) — MASampleSize

<details><summary>Metadata</summary>

```
TITLE: MA Sample Size Calculator: Prospective Meta-Analysis Planning with Information Size and Power Curves
TYPE: methods  |  ESTIMAND: Required number of studies and total sample size for target power
DATA: Meta-analysis planning parameters with assumed heterogeneity and effect sizes
PATH: C:\Models\MASampleSize
```

</details>

### Original (frozen — do not edit)

```
How many studies and what total sample size does a prospective meta-analysis need to achieve adequate statistical power under realistic heterogeneity assumptions? We built a 1,825-line browser application implementing required information size calculation, power curves, and sample size planning for prospective random-effects meta-analysis across binary, continuous, and time-to-event outcomes. The calculator applies the heterogeneity-adjusted information size formula accounting for between-study variance, and generates power curves showing how power changes with the number of studies, per-study sample size, and heterogeneity magnitude. For a typical cardiovascular meta-analysis targeting 80 percent power to detect a risk ratio of 0.80 with moderate heterogeneity, the required information size was 4,200 participants across a minimum of 8 studies. Sensitivity analysis showed that doubling heterogeneity from I-squared 25 to 50 percent increased the required information size by 67 percent. Prospective power calculation could prevent premature meta-analyses that lack sufficient statistical information to detect clinically important effects. The calculator assumes normally distributed study effects and the heterogeneity estimate used for planning may not match the realised heterogeneity once studies are available.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How many studies and what total sample size does a prospective meta-analysis need for adequate statistical power under realistic heterogeneity? We built a 1,825-line browser application implementing required information size, power curves, and sample size planning for prospective random-effects meta-analysis across binary, continuous, and time-to-event outcomes. The calculator applies the heterogeneity-adjusted information size formula and generates power curves showing how power changes with number of studies, sample size, and heterogeneity magnitude. For a cardiovascular meta-analysis targeting 80 percent power to detect a risk ratio of 0.80 with moderate heterogeneity, the required information size was 4,200 participants across 8 studies. Sensitivity analysis showed that doubling heterogeneity from I-squared 25 to 50 percent increased required information size by 67 percent. Prospective power calculation could prevent premature meta-analyses lacking sufficient information to detect clinically important effects. The calculator assumes normally distributed effects and planning heterogeneity may not match realised heterogeneity once studies are available.
<!-- END-REWRITE -->

_Line range 19861-19937 in rewrite-workbook.txt_

---

## Entry 264 ([270/921]) — meta-frontier-bibliography

<details><summary>Metadata</summary>

```
TITLE: Meta-Frontier Annotated Bibliography: Curated Reference Collection for Methods Innovation in Evidence Synthesis
TYPE: methods  |  ESTIMAND: Bibliographic coverage across methods frontiers
DATA: 3,296-line annotated bibliography of meta-analysis methods literature
PATH: C:\Projects\meta-frontier-bibliography
```

</details>

### Original (frozen — do not edit)

```
Can an annotated bibliography organised by methodological frontier systematically map the landscape of innovation in evidence synthesis methods? We curated a 3,296-line interactive bibliography cataloguing published methods across twelve frontiers including network meta-analysis, individual participant data synthesis, living evidence, Bayesian approaches, causal inference, diagnostic accuracy, dose-response, and machine learning applications. Each entry includes structured annotations covering the methodological contribution, validation evidence, computational implementation status, and relevance to the browser-based tool portfolio being developed. The bibliography indexed over 400 publications with cross-references identifying method dependencies, superseded approaches, and gaps where no computational implementation exists. Frontier coverage analysis showed that network meta-analysis and Bayesian methods had the densest citation networks while causal meta-analysis and machine learning applications showed the sparsest coverage with the most recent publication dates. A structured methods bibliography could guide research prioritization by identifying frontiers where innovation has outpaced practical implementation. The bibliography reflects published literature available at compilation time and cannot capture preprints, conference abstracts, or unpublished methodological developments.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can an annotated bibliography organised by methodological frontier map the landscape of innovation in evidence synthesis methods? We curated a 3,296-line interactive bibliography cataloguing methods across twelve frontiers including network meta-analysis, IPD synthesis, living evidence, Bayesian approaches, causal inference, diagnostic accuracy, dose-response, and machine learning. Each entry includes annotations covering the methodological contribution, validation evidence, implementation status, and relevance to the browser-based tool portfolio. The bibliography indexed over 400 publications with cross-references identifying method dependencies, superseded approaches, and implementation gaps. Frontier coverage analysis showed network meta-analysis and Bayesian methods had the densest citation networks while causal meta-analysis showed sparsest coverage with the most recent publication dates. A structured methods bibliography could guide research prioritization by identifying frontiers where innovation outpaces practical implementation. The bibliography reflects published literature at compilation time and cannot capture preprints or unpublished methodological developments.
<!-- END-REWRITE -->

_Line range 19938-20013 in rewrite-workbook.txt_

---

## Entry 265 ([271/921]) — meta-frontier-readiness-atlas

<details><summary>Metadata</summary>

```
TITLE: Meta-Frontier Readiness Atlas: Implementation Maturity Assessment Across Evidence Synthesis Methods
TYPE: methods  |  ESTIMAND: Readiness score per method frontier
DATA: 4,102-line atlas mapping implementation maturity of evidence synthesis methods
PATH: C:\Projects\meta-frontier-readiness-atlas
```

</details>

### Original (frozen — do not edit)

```
How ready are frontier evidence synthesis methods for practical implementation, and where do the largest gaps exist between methodological theory and accessible software tools? We developed a 4,102-line readiness atlas assessing 12 methodological frontiers across five dimensions: theoretical maturity, R package availability, browser tool implementation, validation coverage, and educational resource completeness. Each frontier received a composite readiness score from zero to one hundred based on weighted assessment across the five dimensions. Standard pairwise meta-analysis scored 94 (95% CI 91 to 97) while causal meta-analysis scored 28 (95% CI 22 to 34), representing the widest readiness gap between theoretical development and practical implementation. Network meta-analysis and diagnostic test accuracy occupied intermediate positions with scores reflecting mature R packages but limited browser-based accessibility. The readiness atlas could direct development effort toward frontiers where theoretical advances exist but accessible implementation remains unavailable to non-specialist users. Assessment scores reflect the current state of the author portfolio and general R ecosystem and may undercount implementations in other languages or proprietary platforms.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How ready are frontier evidence synthesis methods for practical implementation, and where do the largest gaps exist between theory and accessible tools? We developed a 4,102-line readiness atlas assessing 12 methodological frontiers across five dimensions: theoretical maturity, R package availability, browser implementation, validation coverage, and educational resource completeness. Each frontier received a composite readiness score from zero to one hundred based on weighted assessment across dimensions. Standard pairwise meta-analysis scored 94 (95% CI 91 to 97) while causal meta-analysis scored 28 (95% CI 22 to 34), representing the widest readiness gap. Network meta-analysis and diagnostic test accuracy occupied intermediate positions with scores reflecting mature R packages but limited browser accessibility. The readiness atlas could direct development toward frontiers where theoretical advances exist but accessible implementation remains unavailable. Assessment scores reflect the current portfolio and R ecosystem and may undercount implementations in other languages or proprietary platforms.
<!-- END-REWRITE -->

_Line range 20014-20089 in rewrite-workbook.txt_

---

## Entry 266 ([272/921]) — minireview

<details><summary>Metadata</summary>

```
TITLE: CRES v4.0: CardioRenal Evidence Synthesizer with Multi-Endpoint Living Meta-Analysis
TYPE: clinical  |  ESTIMAND: Pooled hazard ratio for cardiovascular and renal composite endpoints
DATA: Cardiorenal RCTs including SGLT2i, finerenone, and GLP-1RA trials
PATH: C:\Projects\minireview
```

</details>

### Original (frozen — do not edit)

```
Can a unified evidence synthesis platform simultaneously track cardiovascular and renal outcomes across multiple cardiorenal drug classes with living meta-analysis capabilities? We built CRES v4.0 as a 3,037-line browser application implementing parallel meta-analysis tracks for cardiovascular death, heart failure hospitalisation, kidney disease progression, and composite cardiorenal endpoints across SGLT2 inhibitor, finerenone, and GLP-1 receptor agonist trial data. The platform provides forest plots, cumulative meta-analysis timelines, Trial Sequential Analysis boundaries, GRADE certainty assessment, and head-to-head indirect comparison across drug classes for each endpoint. The pooled hazard ratio for the cardiovascular composite was 0.87 (95% CI 0.82 to 0.93) for SGLT2 inhibitors and 0.86 (95% CI 0.78 to 0.95) for finerenone, with no significant class difference on indirect comparison. Cumulative analysis showed that SGLT2 inhibitor evidence crossed the monitoring boundary after DAPA-CKD while finerenone evidence crossed after FINEARTS-HF. Multi-class living meta-analysis could support formulary decisions by providing real-time comparative cardiorenal evidence across emerging drug classes. The indirect comparisons assume exchangeability of trial populations across drug classes which may not hold given different recruitment criteria.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a unified platform simultaneously track cardiovascular and renal outcomes across multiple cardiorenal drug classes with living meta-analysis? We built CRES v4.0 as a 3,037-line browser application implementing parallel meta-analysis tracks for cardiovascular death, heart failure hospitalisation, kidney disease progression, and composite endpoints across SGLT2 inhibitor, finerenone, and GLP-1RA data. The platform provides forest plots, cumulative timelines, Trial Sequential Analysis boundaries, GRADE assessment, and indirect comparison across drug classes for each endpoint. The pooled hazard ratio for the cardiovascular composite was 0.87 (95% CI 0.82 to 0.93) for SGLT2 inhibitors and 0.86 (95% CI 0.78 to 0.95) for finerenone. Cumulative analysis showed SGLT2 inhibitor evidence crossed the monitoring boundary after DAPA-CKD while finerenone crossed after FINEARTS-HF. Multi-class living meta-analysis could support formulary decisions by providing real-time comparative cardiorenal evidence. The indirect comparisons assume exchangeability of trial populations across drug classes which may not hold given different recruitment criteria.
<!-- END-REWRITE -->

_Line range 20090-20165 in rewrite-workbook.txt_

---

## Entry 267 ([273/921]) — new-app

<details><summary>Metadata</summary>

```
TITLE: Meta-Analysis Platform v2.0: Comprehensive Browser-Based Evidence Synthesis
TYPE: methods  |  ESTIMAND: Pooled effect estimate with heterogeneity statistics
DATA: User-entered or imported meta-analysis study data
PATH: C:\Projects\new-app
```

</details>

### Original (frozen — do not edit)

```
Can a comprehensive browser-based meta-analysis platform provide statistical methods comparable to R packages while remaining accessible to researchers without programming experience? We developed Meta-Analysis Platform v2.0 as a 590-line browser application implementing fixed-effect and random-effects meta-analysis with inverse-variance weighting, DerSimonian-Laird and REML heterogeneity estimation, forest plot generation, and funnel plot visualization. The platform accepts manual data entry or CSV import of study-level effect sizes and standard errors, producing pooled estimates with confidence and prediction intervals. Pooled estimates matched R metafor output within four decimal places across all validation datasets including binary, continuous, and pre-computed effect size inputs. Interactive forest plots rendered study weights, confidence intervals, and diamond summaries in publication-quality format exportable as SVG or PNG. A lightweight browser meta-analysis platform could serve as an accessible entry point for researchers performing their first quantitative evidence synthesis. The platform implements standard pairwise methods and does not yet support network meta-analysis, meta-regression, or diagnostic test accuracy models.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a browser-based meta-analysis platform provide methods comparable to R packages while remaining accessible to non-programmers? We developed Meta-Analysis Platform v2.0 as a 590-line application implementing fixed and random-effects meta-analysis with inverse-variance weighting, DerSimonian-Laird and REML heterogeneity estimation, and forest and funnel plot generation. The platform accepts manual data entry or CSV import of study-level effect sizes and standard errors, producing pooled estimates with confidence and prediction intervals. Pooled estimates matched R metafor output within four decimal places across all validation datasets including binary, continuous, and pre-computed inputs. Interactive forest plots rendered study weights, confidence intervals, and diamond summaries in publication-quality format exportable as SVG or PNG. A lightweight browser platform could serve as an accessible entry point for researchers performing their first quantitative evidence synthesis. The platform implements standard pairwise methods and does not yet support network meta-analysis or meta-regression.
<!-- END-REWRITE -->

_Line range 20166-20241 in rewrite-workbook.txt_

---

## Entry 268 ([274/921]) — NMA

<details><summary>Metadata</summary>

```
TITLE: NMA: Surrogate-Assisted Network Meta-Analysis Package
TYPE: methods  |  ESTIMAND: Network pooled treatment effect with surrogate endpoint calibration
DATA: Multi-arm NMA datasets with surrogate and final endpoint data
PATH: C:\Projects\NMA
```

</details>

### Original (frozen — do not edit)

```
Can surrogate endpoint data be incorporated into network meta-analysis to improve treatment effect estimation when final endpoint data are incomplete across the evidence network? We developed a surrogate-assisted NMA package implementing surrogate threshold effect calibration, bivariate meta-analysis of surrogate-final endpoint correlation, and network-level surrogate adjustment for treatment rankings. The method estimates the surrogate-final endpoint association from trials reporting both endpoints, then applies this calibration to adjust treatment comparisons from trials reporting only surrogate data. In simulation studies the surrogate-adjusted NMA reduced mean squared error of treatment rankings by 34 percent (95% CI 27 to 41) compared with analyses restricted to final endpoint data only. Calibrated surrogate inclusion increased the effective network connectivity, converting previously disconnected network components into connected networks amenable to indirect comparison. Surrogate-assisted NMA could enable more comprehensive treatment comparisons in oncology and cardiovascular networks where regulatory approval increasingly relies on surrogate endpoints. The approach assumes a stable surrogate-final endpoint relationship across treatments and may produce biased rankings if surrogate validity varies by mechanism of action.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can surrogate endpoint data be incorporated into network meta-analysis to improve treatment estimation when final endpoint data are incomplete? We developed a surrogate-assisted NMA package implementing surrogate threshold calibration, bivariate meta-analysis of surrogate-final correlation, and network-level surrogate adjustment for treatment rankings. The method estimates the surrogate-final association from trials reporting both endpoints then applies calibration to adjust comparisons from trials reporting only surrogate data. In simulation the surrogate-adjusted NMA reduced mean squared error of rankings by 34 percent (95% CI 27 to 41) compared with final-endpoint-only analyses. Calibrated surrogate inclusion increased effective network connectivity, converting disconnected components into connected networks amenable to indirect comparison. Surrogate-assisted NMA could enable comprehensive treatment comparisons in networks where regulatory approval increasingly relies on surrogate endpoints. The approach assumes a stable surrogate-final relationship across treatments and may produce biased rankings if surrogate validity varies by mechanism.
<!-- END-REWRITE -->

_Line range 20242-20317 in rewrite-workbook.txt_

---

## Entry 269 ([275/921]) — oman

<details><summary>Metadata</summary>

```
TITLE: Oman Evidence OS: Comprehensive Health Technology Assessment Platform for the Sultanate of Oman
TYPE: methods  |  ESTIMAND: HTA recommendation concordance with established agencies
DATA: Oman essential medicines list, WHO cost-effectiveness thresholds, regional disease burden data
PATH: C:\Projects\oman
```

</details>

### Original (frozen — do not edit)

```
Can a localised health technology assessment platform produce structured HTA recommendations calibrated to the healthcare context of the Sultanate of Oman? We developed Oman Evidence OS as a 1,117-line browser application implementing multi-criteria decision analysis, cost-effectiveness thresholds adjusted to Omani GDP per capita, disease burden prioritisation using regional epidemiological data, and budget impact modelling for the national formulary. The platform applies WHO-CHOICE cost-effectiveness thresholds with Omani purchasing power adjustment and generates structured recommendation reports including clinical evidence summaries, economic evaluation, and equity impact assessments. Recommendations produced by the platform showed 87 percent concordance (95% CI 78 to 93) with established HTA agency decisions for the same interventions when tested against 15 benchmark pharmaceutical assessments. Budget impact projections incorporated Oman-specific utilisation rates, pricing structures, and patient population estimates from the national health information system. Localised HTA tools could support evidence-informed formulary decisions in countries developing national assessment capacity. The platform uses published data sources and economic parameters that require regular updating to reflect current Omani healthcare costs and epidemiological trends.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a localised HTA platform produce recommendations calibrated to the healthcare context of the Sultanate of Oman? We developed Oman Evidence OS as a 1,117-line browser application implementing multi-criteria decision analysis, cost-effectiveness thresholds adjusted to Omani GDP per capita, disease burden prioritisation, and budget impact modelling for the national formulary. The platform applies WHO-CHOICE thresholds with purchasing power adjustment and generates recommendation reports including clinical summaries, economic evaluation, and equity impact assessments. Recommendations showed 87 percent concordance (95% CI 78 to 93) with established HTA agency decisions when tested against 15 benchmark pharmaceutical assessments. Budget impact projections incorporated Oman-specific utilisation rates, pricing structures, and patient population estimates from the national health information system. Localised HTA tools could support evidence-informed formulary decisions in countries developing national assessment capacity. The platform uses published data sources and economic parameters requiring regular updating to reflect current Omani healthcare costs.
<!-- END-REWRITE -->

_Line range 20318-20393 in rewrite-workbook.txt_

---

## Entry 270 ([276/921]) — Pairwise humble

<details><summary>Metadata</summary>

```
TITLE: Pairwise Pro v2.2: Decision-Driven Meta-Analysis Platform with 19,584 Lines of Interactive Evidence Synthesis
TYPE: methods  |  ESTIMAND: Pooled effect estimate with 15+ heterogeneity estimators
DATA: Built-in clinical datasets and user-imported meta-analysis data
PATH: C:\Projects\Pairwise humble
```

</details>

### Original (frozen — do not edit)

```
Can a comprehensive browser-based pairwise meta-analysis platform match the analytical depth of R metafor while providing interactive decision-support features for clinical evidence synthesis? We developed Pairwise Pro v2.2 as a 19,584-line single-file application implementing 15 heterogeneity estimators, 6 confidence interval methods, subgroup analysis, meta-regression, cumulative meta-analysis, leave-one-out diagnostics, 8 publication bias methods, GOSH plots, GRADE certainty assessment, and fragility index computation. The platform provides forest plots, funnel plots, Baujat plots, Galbraith plots, L-Abbe plots, radial plots, and trim-and-fill visualisation with export to SVG and publication-quality formats. Pooled estimates matched R metafor across all 15 heterogeneity estimators within four decimal places for the BCG vaccine and aspirin benchmark datasets. Interactive decision panels integrate the pooled estimate with GRADE certainty, fragility index, and prediction interval into a structured clinical summary with traffic-light certainty signalling. Integrating multiple analytical perspectives into a single interactive platform could streamline the path from meta-analytic computation to clinical decision-making. The application is limited to pairwise comparisons and cannot perform network meta-analysis or individual participant data synthesis.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a browser-based pairwise meta-analysis platform match R metafor analytical depth while providing interactive decision-support features? We developed Pairwise Pro v2.2 as a 19,584-line application implementing 15 heterogeneity estimators, 6 confidence interval methods, subgroup analysis, meta-regression, cumulative analysis, leave-one-out diagnostics, 8 publication bias methods, and GRADE assessment. The platform provides forest, funnel, Baujat, Galbraith, L-Abbe, and radial plots with trim-and-fill visualisation in publication-quality exportable formats. Pooled estimates matched R metafor across all 15 heterogeneity estimators within four decimal places for BCG vaccine and aspirin benchmark datasets. Interactive decision panels integrate the pooled estimate with GRADE certainty, fragility index, and prediction interval into a structured clinical summary. Integrating multiple analytical perspectives into a single platform could streamline the path from computation to clinical decision-making. The application is limited to pairwise comparisons and cannot perform network meta-analysis or individual participant data synthesis.
<!-- END-REWRITE -->

_Line range 20394-20469 in rewrite-workbook.txt_

---

## Entry 271 ([277/921]) — PFA_AF_LivingMeta

<details><summary>Metadata</summary>

```
TITLE: PFA in AF Living Meta-Analysis: Pulsed Field Ablation for Atrial Fibrillation Evidence Surveillance
TYPE: clinical  |  ESTIMAND: Pooled success rate and complication rate with monitoring boundaries
DATA: Published PFA clinical studies and RCTs for atrial fibrillation ablation
PATH: C:\Projects\PFA_AF_LivingMeta
```

</details>

### Original (frozen — do not edit)

```
Can a living meta-analysis platform provide continuously updated pooled efficacy and safety estimates for pulsed field ablation in atrial fibrillation as this emerging technology matures? We built a 2,657-line browser application implementing cumulative meta-analysis with Trial Sequential Analysis monitoring for freedom from atrial fibrillation recurrence, procedural complications, pulmonary vein isolation durability, and esophageal injury rates. The platform incorporates data from published PFA studies with an architecture supporting automated updating as new studies are published. Pooled freedom from AF recurrence at 12 months was 78 percent (95% CI 73 to 83) across included studies with moderate heterogeneity reflecting differences in ablation protocols and patient selection criteria. Trial Sequential Analysis monitoring showed that the cumulative evidence had not yet crossed the information size boundary for definitive conclusions on long-term efficacy compared to thermal ablation. Living evidence surveillance could track PFA technology maturation and signal when sufficient evidence exists for updating clinical practice guidelines. The evidence base consists primarily of single-arm studies and early-phase comparisons with limited long-term follow-up data.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a living meta-analysis platform provide continuously updated efficacy and safety estimates for pulsed field ablation in atrial fibrillation? We built a 2,657-line browser application implementing cumulative meta-analysis with Trial Sequential Analysis monitoring for freedom from AF recurrence, complications, PV isolation durability, and esophageal injury rates. The platform incorporates published PFA studies with architecture supporting automated updating as new evidence emerges. Pooled freedom from AF recurrence at 12 months was 78 percent (95% CI 73 to 83) with moderate heterogeneity reflecting differences in ablation protocols and patient selection. Trial Sequential Analysis showed that cumulative evidence had not yet crossed the information size boundary for definitive conclusions on long-term efficacy. Living evidence surveillance could track PFA technology maturation and signal when sufficient evidence exists for updating practice guidelines. The evidence base consists primarily of single-arm studies and early comparisons with limited long-term follow-up.
<!-- END-REWRITE -->

_Line range 20470-20546 in rewrite-workbook.txt_

---

## Entry 272 ([278/921]) — rayyanreplacement

<details><summary>Metadata</summary>

```
TITLE: Screenr v11.0: World-Class Offline-First Systematic Review Platform Replacing Rayyan and Covidence
TYPE: methods  |  ESTIMAND: Screening throughput and inter-rater agreement metrics
DATA: Systematic review reference libraries with relevance labels for screening benchmarks
PATH: C:\Projects\rayyanreplacement
```

</details>

### Original (frozen — do not edit)

```
Can an offline-first browser application provide a complete systematic review workflow from screening through meta-analysis that rivals commercial platforms like Rayyan and Covidence? We developed Screenr as a 32,814-line comprehensive platform implementing title-abstract screening with machine learning prioritisation, full-text screening, structured data extraction, risk of bias assessment using RoB 2 and ROBINS-I frameworks, and integrated random-effects meta-analysis. The application operates entirely offline with IndexedDB storage, supports multi-reviewer workflows with conflict resolution, and provides PRISMA flow diagram generation from recorded screening decisions. Machine-learning-assisted screening achieved 95 percent recall while reducing screening workload by 67 percent (95% CI 62 to 72) compared to random ordering across three benchmark review datasets. Inter-rater agreement tools calculated Cohen kappa and percentage agreement in real time, flagging reviewer pairs with kappa below 0.70 for calibration. A free offline-first platform could eliminate subscription barriers that limit systematic review adoption in low-resource research settings. The machine learning model requires a minimum of 50 labelled abstracts for effective prioritisation and may underperform for highly technical or interdisciplinary review topics.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can an offline-first browser application provide a complete systematic review workflow rivalling commercial platforms like Rayyan and Covidence? We developed Screenr as a 32,814-line platform implementing ML-assisted screening, full-text review, structured extraction, risk of bias assessment using RoB 2 and ROBINS-I, and integrated meta-analysis. The application operates entirely offline with IndexedDB storage, supports multi-reviewer workflows with conflict resolution, and generates PRISMA flow diagrams from screening decisions. ML-assisted screening achieved 95 percent recall while reducing workload by 67 percent (95% CI 62 to 72) compared to random ordering across three benchmark datasets. Inter-rater agreement tools calculated Cohen kappa and percentage agreement in real time, flagging pairs with kappa below 0.70 for calibration. A free offline platform could eliminate subscription barriers limiting systematic review adoption in low-resource settings. The ML model requires minimum 50 labelled abstracts for effective prioritisation and may underperform for highly interdisciplinary topics.
<!-- END-REWRITE -->

_Line range 20547-20622 in rewrite-workbook.txt_

---

## Entry 273 ([279/921]) — research-orbit-control

<details><summary>Metadata</summary>

```
TITLE: Research Orbit Control: Portfolio Management Dashboard for Evidence Synthesis Projects
TYPE: methods  |  ESTIMAND: Portfolio completion rate and project status tracking
DATA: Project metadata from the evidence synthesis tool portfolio
PATH: C:\Projects\research-orbit-control
```

</details>

### Original (frozen — do not edit)

```
Can a portfolio management dashboard provide real-time visibility into the status of dozens of evidence synthesis projects to support prioritisation and resource allocation decisions? We developed Research Orbit Control as a 228-line browser application displaying project status, completion metrics, dependency relationships, and publication readiness across the full evidence synthesis tool portfolio. The dashboard aggregates metadata from project configuration files to show per-project test pass rates, line counts, review status, and target journal assignments in a visual orbital layout. All portfolio projects were successfully indexed with accurate status representation matching their current development state. Project dependency mapping identified three critical-path chains where delays in one tool would cascade to downstream applications requiring its outputs. Portfolio-level visibility could help solo researchers and small teams allocate development time toward the highest-impact bottleneck rather than working on readily available but low-priority tasks. The dashboard provides a point-in-time snapshot and requires manual refresh to reflect changes made since the last metadata synchronisation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a portfolio dashboard provide real-time visibility into dozens of evidence synthesis projects to support prioritisation decisions? We developed Research Orbit Control as a 228-line browser application displaying project status, completion metrics, dependencies, and publication readiness across the full tool portfolio. The dashboard aggregates metadata from configuration files showing per-project test pass rates, line counts, review status, and target journal assignments. All portfolio projects were successfully indexed with accurate status matching their current development state. Dependency mapping identified three critical-path chains where delays in one tool would cascade to downstream applications requiring its outputs. Portfolio-level visibility could help small teams allocate development time toward the highest-impact bottleneck rather than low-priority tasks. The dashboard provides a point-in-time snapshot and requires manual refresh to reflect changes since the last metadata synchronisation.
<!-- END-REWRITE -->

_Line range 20623-20698 in rewrite-workbook.txt_

---

## Entry 274 ([280/921]) — Scripts

<details><summary>Metadata</summary>

```
TITLE: Scripts: Utility Script Collection for Evidence Synthesis Pipeline Automation
TYPE: methods  |  ESTIMAND: Pipeline automation coverage across evidence synthesis tasks
DATA: 42 utility scripts covering data processing, validation, and deployment tasks
PATH: C:\Projects\Scripts
```

</details>

### Original (frozen — do not edit)

```
Can a curated collection of utility scripts automate repetitive evidence synthesis pipeline tasks from data extraction through publication-ready output generation? We assembled 42 utility scripts in Python, R, and Bash implementing common pipeline operations including CSV to meta-analysis format conversion, forest plot batch generation, reference list deduplication, PRISMA flow statistics extraction, and automated test execution across the browser tool portfolio. Each script follows a standardised interface pattern with command-line arguments, progress reporting, and error logging to enable composable pipeline construction. The collection covered 85 percent of identified repetitive pipeline tasks (95% CI 78 to 91) across the evidence synthesis workflow from study identification through manuscript submission. Scripts maintained backward compatibility across three portfolio update cycles, with a breaking change rate of 2 per update cycle on average. A standardised utility collection could reduce pipeline setup time for new meta-analysis projects from days to hours by providing tested building blocks. The scripts assume specific input formats from the portfolio tools and may require adaptation for use with external meta-analysis software outputs.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a curated utility script collection automate repetitive evidence synthesis pipeline tasks from data extraction through output generation? We assembled 42 scripts in Python, R, and Bash implementing CSV conversion, forest plot batch generation, reference deduplication, PRISMA statistics extraction, and automated test execution across the tool portfolio. Each script follows a standardised interface with command-line arguments, progress reporting, and error logging for composable pipeline construction. The collection covered 85 percent of identified repetitive pipeline tasks (95% CI 78 to 91) across the synthesis workflow from study identification through submission. Scripts maintained backward compatibility across three portfolio update cycles with a breaking change rate of 2 per cycle on average. A standardised utility collection could reduce pipeline setup time for new meta-analysis projects from days to hours. The scripts assume specific input formats from portfolio tools and may require adaptation for external meta-analysis software outputs.
<!-- END-REWRITE -->

_Line range 20699-20774 in rewrite-workbook.txt_

---

## Entry 275 ([281/921]) — Stories

<details><summary>Metadata</summary>

```
TITLE: When Certainty Kills: The CAST Story and Narrative Evidence Communication
TYPE: methods  |  ESTIMAND: Narrative engagement and evidence comprehension metrics
DATA: CAST trial (Cardiac Arrhythmia Suppression Trial) historical case study
PATH: C:\Projects\Stories
```

</details>

### Original (frozen — do not edit)

```
Can narrative storytelling communicate the consequences of acting on biological plausibility without randomised evidence more effectively than statistical summaries alone? We developed a 1,921-line interactive narrative based on the Cardiac Arrhythmia Suppression Trial, where anti-arrhythmic drugs that suppressed premature ventricular contractions were expected to reduce mortality but instead increased it by 350 percent. The story walks through the clinical reasoning that led to widespread prescribing, the ethical debates around randomisation when a biological mechanism seemed clear, and the trial results that revealed the fatal gap between surrogate endpoint suppression and patient-important outcomes. The CAST narrative illustrates a 350 percent increase in mortality (95% CI 170 to 610) among patients receiving encainide or flecainide compared to placebo. Interactive elements allow readers to predict outcomes at each decision point before revealing the actual results, engaging active learning rather than passive information consumption. Narrative evidence communication could complement statistical presentations in guideline development and medical education contexts. The single-case narrative format cannot represent the full distribution of surrogate endpoint failures across therapeutic areas.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can narrative storytelling communicate consequences of acting on biological plausibility without randomised evidence more effectively than statistics alone? We developed a 1,921-line interactive narrative based on the Cardiac Arrhythmia Suppression Trial, where anti-arrhythmic drugs expected to reduce mortality instead increased it. The story traces clinical reasoning behind widespread prescribing, ethical debates around randomisation when mechanism seemed clear, and trial results revealing the gap between surrogate suppression and patient outcomes. The CAST narrative illustrates a 350 percent increase in mortality (95% CI 170 to 610) among patients receiving encainide or flecainide compared to placebo. Interactive elements allow readers to predict outcomes at each decision point before revealing results, engaging active learning rather than passive consumption. Narrative evidence communication could complement statistical presentations in guideline development and medical education. The single-case format cannot represent the full distribution of surrogate endpoint failures across therapeutic areas.
<!-- END-REWRITE -->

_Line range 20775-20850 in rewrite-workbook.txt_

---

## Entry 276 ([282/921]) — superapp

<details><summary>Metadata</summary>

```
TITLE: Living Meta-Analysis Starter: Lightweight Template for Rapid Living Evidence Applications
TYPE: methods  |  ESTIMAND: Template deployment time and customisation effort
DATA: Template structure for living meta-analysis browser applications
PATH: C:\Projects\superapp
```

</details>

### Original (frozen — do not edit)

```
Can a lightweight application template reduce the time required to deploy a new living meta-analysis from days of development to minutes of configuration? We created an 80-line browser application template providing the minimal scaffolding for a living meta-analysis tool including data input, random-effects pooling, forest plot rendering, and cumulative timeline visualisation. The template implements a study data schema with effect size, standard error, and chronological ordering, connected to a DerSimonian-Laird pooling engine with automatic forest plot and cumulative meta-analysis chart generation. Customising the template for a new clinical topic required changing only the study data array and title, with pooling and visualisation updating automatically in under five minutes. The template maintained numerical agreement with R metafor within four decimal places for all tested configurations while remaining under 100 lines of readable code. A minimal starter template could accelerate living evidence applications by providing a tested computational core that topic experts can populate without programming expertise. The template implements only basic random-effects pooling and would require substantial extension for heterogeneity diagnostics, bias assessment, or monitoring boundaries.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a lightweight template reduce deployment time for a new living meta-analysis from days to minutes of configuration? We created an 80-line browser template providing minimal scaffolding including data input, random-effects pooling, forest plot rendering, and cumulative timeline visualisation. The template implements a study data schema with effect size and standard error connected to a DerSimonian-Laird pooling engine with automatic chart generation. Customising for a new clinical topic required changing only the study data array and title, with pooling and visualisation updating automatically in under five minutes. The template maintained numerical agreement with R metafor within four decimal places for all tested configurations while remaining under 100 lines. A minimal starter template could accelerate living evidence applications by providing a tested core that topic experts can populate without programming. The template implements basic random-effects pooling and would require extension for heterogeneity diagnostics, bias assessment, or monitoring boundaries.
<!-- END-REWRITE -->

_Line range 20851-20926 in rewrite-workbook.txt_

---

## Entry 277 ([283/921]) — tower

<details><summary>Metadata</summary>

```
TITLE: Tower: Multi-Language Build and Deployment Infrastructure for Evidence Synthesis Projects
TYPE: methods  |  ESTIMAND: Build success rate and deployment pipeline reliability
DATA: Build configurations across Bash, Python, and JavaScript project types
PATH: C:\Projects\tower
```

</details>

### Original (frozen — do not edit)

```
Can a unified build and deployment system manage the heterogeneous infrastructure requirements of a large evidence synthesis project portfolio spanning multiple programming languages? We developed Tower as a multi-language build infrastructure supporting Bash, Python, and JavaScript projects with standardised build commands, test execution, dependency management, and deployment scripts across 26 project components. The system implements language-specific build adapters that normalise the build-test-deploy cycle into a consistent interface regardless of whether the underlying project uses npm, pip, or shell scripts. All 26 managed projects achieved successful builds through the unified interface, with build failures correctly attributed to project-specific issues rather than infrastructure problems. Automated dependency resolution detected and reported 4 circular dependencies across the project portfolio that had previously caused intermittent build failures. Unified build infrastructure could reduce the maintenance burden of managing many small projects by centralising common operations and dependency tracking. The system supports the current project technology stack and would require new adapters for R, Rust, or compiled language projects.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a unified build system manage heterogeneous infrastructure requirements across a large evidence synthesis project portfolio? We developed Tower as multi-language build infrastructure supporting Bash, Python, and JavaScript with standardised build, test, dependency management, and deployment scripts across 26 components. The system implements language-specific adapters normalising the build-test-deploy cycle into a consistent interface regardless of underlying package managers. All 26 managed projects achieved successful builds through the unified interface, with failures correctly attributed to project-specific issues. Automated dependency resolution detected 4 circular dependencies that had previously caused intermittent build failures across the portfolio. Unified build infrastructure could reduce maintenance burden of many small projects by centralising common operations and dependency tracking. The system supports the current technology stack and would require new adapters for R, Rust, or compiled language projects.
<!-- END-REWRITE -->

_Line range 20927-21002 in rewrite-workbook.txt_

---

## Entry 278 ([284/921]) — tower_js

<details><summary>Metadata</summary>

```
TITLE: Tower JS: JavaScript Runtime for Evidence Synthesis Pipeline Orchestration
TYPE: methods  |  ESTIMAND: Pipeline execution reliability and task completion rate
DATA: Pipeline task definitions for evidence synthesis workflow automation
PATH: C:\Projects\tower_js
```

</details>

### Original (frozen — do not edit)

```
Can a JavaScript-based pipeline orchestrator coordinate complex evidence synthesis workflows involving data extraction, analysis, validation, and report generation across multiple tool outputs? We developed Tower JS as a lightweight pipeline runtime implementing task dependency resolution, parallel execution of independent tasks, error recovery with configurable retry policies, and structured logging for audit trails. The orchestrator accepts pipeline definitions as JSON task graphs specifying tool invocations, data transformations, and validation checkpoints that must pass before downstream tasks execute. All test pipeline configurations completed successfully with correct task ordering, and deliberate failure injection triggered appropriate retry and fallback behaviours in every tested scenario. Parallel execution of independent pipeline branches reduced end-to-end runtime by 43 percent compared to sequential execution for a representative evidence synthesis workflow. JavaScript-based orchestration could provide pipeline automation accessible to the browser-tool ecosystem without requiring external workflow engines. The orchestrator runs in Node.js and cannot directly invoke R scripts or compiled binaries without shell execution wrappers.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a JavaScript pipeline orchestrator coordinate evidence synthesis workflows involving extraction, analysis, validation, and report generation? We developed Tower JS implementing task dependency resolution, parallel execution, error recovery with configurable retry, and structured logging for audit trails. The orchestrator accepts JSON task graphs specifying tool invocations, data transformations, and validation checkpoints that must pass before downstream tasks execute. All test configurations completed successfully with correct ordering; deliberate failure injection triggered appropriate retry and fallback behaviours in every scenario. Parallel execution of independent branches reduced end-to-end runtime by 43 percent compared to sequential execution for a representative workflow. JavaScript orchestration could provide pipeline automation accessible to the browser-tool ecosystem without external workflow engines. The orchestrator runs in Node.js and cannot directly invoke R scripts or compiled binaries without shell execution wrappers.
<!-- END-REWRITE -->

_Line range 21003-21078 in rewrite-workbook.txt_

---

## Entry 279 ([285/921]) — Tricuspid_TEER_LivingMeta

<details><summary>Metadata</summary>

```
TITLE: Tricuspid TEER Living Meta-Analysis: Edge-Repair Evidence Surveillance for Severe Tricuspid Regurgitation
TYPE: clinical  |  ESTIMAND: Pooled reduction in tricuspid regurgitation grade
DATA: Published studies on transcatheter edge-to-edge repair for tricuspid regurgitation
PATH: C:\Projects\Tricuspid_TEER_LivingMeta
```

</details>

### Original (frozen — do not edit)

```
Can a living meta-analysis platform track the emerging evidence for transcatheter edge-to-edge repair of severe tricuspid regurgitation as new studies report? We initiated a living meta-analysis of TEER for tricuspid regurgitation as a 153-line browser application implementing cumulative meta-analysis with automated pooling of tricuspid regurgitation grade reduction, functional improvement, and procedural safety outcomes. The platform is configured to incorporate data from TRILUMINATE and subsequent trials as they publish results. Initial pooled data showed a mean reduction of 1.8 tricuspid regurgitation grades (95% CI 1.4 to 2.2) with procedural success rates exceeding 90 percent across included early studies. The living framework monitors whether cumulative evidence has crossed pre-specified decision boundaries for recommending TEER over medical management alone. Continuous evidence surveillance for emerging transcatheter therapies could inform device adoption timing and guideline updates as the evidence base matures from first-in-human to randomised comparison. The current evidence consists primarily of single-arm registries and the living platform requires randomised comparative data for meaningful treatment effect estimation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a living meta-analysis track emerging evidence for transcatheter edge-to-edge repair of severe tricuspid regurgitation? We initiated a living analysis as a 153-line browser application implementing cumulative meta-analysis with automated pooling of TR grade reduction, functional improvement, and procedural safety. The platform is configured to incorporate TRILUMINATE and subsequent trial data as they publish. Initial pooled data showed a mean reduction of 1.8 tricuspid regurgitation grades (95% CI 1.4 to 2.2) with procedural success exceeding 90 percent across early studies. The living framework monitors whether cumulative evidence has crossed pre-specified boundaries for recommending TEER over medical management alone. Continuous surveillance for emerging transcatheter therapies could inform device adoption timing and guideline updates as evidence matures. Current evidence consists primarily of single-arm registries and the platform requires randomised comparative data for meaningful treatment effect estimation.
<!-- END-REWRITE -->

_Line range 21079-21155 in rewrite-workbook.txt_

---

## Entry 280 ([286/921]) — truthcert-openclaw-supermemory-stack

<details><summary>Metadata</summary>

```
TITLE: TruthCert-OpenClaw-Supermemory Stack: Fail-Closed Certifier Architecture with Local-First Memory
TYPE: methods  |  ESTIMAND: Certification protocol compliance rate
DATA: Architecture specification for the TruthCert certification, OpenClaw consultation, and Supermemory persistence stack
PATH: C:\Projects\truthcert-openclaw-supermemory-stack
```

</details>

### Original (frozen — do not edit)

```
Can a three-layer architecture combining fail-closed certification, structured consultation, and local-first persistent memory provide trustworthy numeric claims in LLM-assisted evidence synthesis? We designed the TruthCert-OpenClaw-Supermemory stack as an integrated system where TruthCert enforces per-claim provenance verification, OpenClaw implements structured planning and review consultation, and Supermemory provides namespace-isolated local memory that explicitly cannot serve as evidence. The architecture specification defines strict boundaries between layers: memory informs planning but never enters certified claims, consultation produces structured plans but cannot override certification failures, and certification requires complete provenance chains for every atomic numeric claim. Protocol compliance analysis confirmed that all simulated certification attempts correctly rejected claims referencing memory as evidence source. The three-layer separation prevents the common failure mode where LLM-generated text containing uncertified numbers passes through review without provenance verification. Structured separation of planning, verification, and persistence could establish a reference architecture for trustworthy AI-assisted research. The specification has not yet been validated in a production deployment with real peer-reviewed publications.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a three-layer architecture combining fail-closed certification, structured consultation, and local-first memory provide trustworthy numeric claims? We designed the TruthCert-OpenClaw-Supermemory stack where TruthCert enforces per-claim provenance verification, OpenClaw implements structured planning and review, and Supermemory provides namespace-isolated memory explicitly excluded from evidence. The specification defines strict boundaries: memory informs planning but never enters certified claims, consultation produces plans but cannot override certification failures, and certification requires complete provenance chains. Protocol compliance analysis confirmed all simulated attempts correctly rejected claims referencing memory as evidence source. The three-layer separation prevents the failure mode where uncertified numbers pass through review without provenance verification. Structured separation of planning, verification, and persistence could establish a reference architecture for trustworthy AI-assisted research. The specification has not yet been validated in production deployment with real peer-reviewed publications.
<!-- END-REWRITE -->

_Line range 21156-21231 in rewrite-workbook.txt_

---

## Entry 281 ([287/921]) — TruthCert-Validation-Papers

<details><summary>Metadata</summary>

```
TITLE: TruthCert Validation Papers: Comprehensive Validation Studies for Fail-Closed Certification v3.1.0
TYPE: methods  |  ESTIMAND: Validation pass rate across certification scenarios
DATA: Synthetic and real-world certification test scenarios for TruthCert v3.1.0
PATH: C:\Projects\TruthCert-Validation-Papers
```

</details>

### Original (frozen — do not edit)

```
Can the TruthCert v3.1.0 certification protocol be validated through systematic testing of synthetic and real-world certification scenarios covering all twelve extension domains? We designed a comprehensive validation study applying TruthCert certification to synthetic bundles with known correct and corrupted claims alongside real meta-analysis outputs from the evidence synthesis tool portfolio. The validation tested provenance chain completeness, cross-witness arbitration, hash integrity, estimand scope-locking, and domain-specific validator pack accuracy across all twelve extension domains. TruthCert correctly certified 98 percent of valid bundles and rejected 100 percent of corrupted bundles (95% CI 97 to 100 for specificity) across all tested scenarios. False negatives occurred exclusively in edge cases where valid bundles used non-standard evidence locator formats not yet covered by the validator pack specifications. Systematic protocol validation could establish confidence in certification accuracy before deploying TruthCert for production manuscript verification. The validation uses controlled scenarios and real-world certification performance may differ when applied to bundles from heterogeneous research groups using diverse analysis tools.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can TruthCert v3.1.0 be validated through systematic testing covering all twelve extension domains with synthetic and real scenarios? We designed comprehensive validation applying certification to synthetic bundles with known correct and corrupted claims alongside real meta-analysis outputs from the portfolio. Testing covered provenance chain completeness, cross-witness arbitration, hash integrity, estimand scope-locking, and domain-specific validator accuracy across all twelve domains. TruthCert correctly certified 98 percent of valid bundles and rejected 100 percent of corrupted bundles (95% CI 97 to 100 for specificity). False negatives occurred exclusively in edge cases where valid bundles used non-standard evidence locator formats not covered by validator specifications. Systematic protocol validation could establish confidence in certification accuracy before production deployment. The validation uses controlled scenarios and real-world performance may differ for bundles from heterogeneous research groups using diverse tools.
<!-- END-REWRITE -->

_Line range 21232-21307 in rewrite-workbook.txt_

---

## Entry 282 ([288/921]) — TruthCert_v3.1.0_modeling

<details><summary>Metadata</summary>

```
TITLE: TruthCert v3.1.0 Modeling Pack: Statistical Models for Certification Threshold Calibration
TYPE: methods  |  ESTIMAND: Optimal certification threshold (sensitivity-specificity trade-off)
DATA: Certification outcome data from synthetic and portfolio validation scenarios
PATH: C:\Projects\TruthCert_v3.1.0_modeling
```

</details>

### Original (frozen — do not edit)

```
Can statistical modelling of certification outcomes identify optimal threshold parameters that maximise sensitivity while maintaining zero false certification in the TruthCert protocol? We developed a modelling pack implementing ROC analysis, threshold optimisation, and sensitivity analysis for TruthCert certification parameters across witness count requirements, hash tolerance windows, and provenance chain depth criteria. The models used certification outcome data from synthetic validation scenarios to fit logistic regression and decision tree classifiers predicting certification accuracy as a function of configurable threshold parameters. Optimal threshold selection achieved 98.5 percent sensitivity at zero false certification rate (95% CI 96.2 to 99.4) with the constraint that no corrupted bundle should ever receive certification. Sensitivity analysis showed that witness count had the largest marginal effect on certification accuracy, with three-witness arbitration providing a 12 percentage point improvement over single-witness verification. Threshold modelling could enable context-specific TruthCert deployment where different domains require different sensitivity-specificity trade-offs. The models were calibrated on synthetic data and threshold recommendations may require recalibration when applied to domain-specific certification scenarios with different corruption prevalence.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can statistical modelling identify optimal threshold parameters maximising sensitivity while maintaining zero false certification? We developed a modelling pack implementing ROC analysis, threshold optimisation, and sensitivity analysis for TruthCert parameters across witness count, hash tolerance, and provenance chain depth criteria. Models used synthetic validation data to fit logistic regression and decision tree classifiers predicting certification accuracy as a function of configurable thresholds. Optimal selection achieved 98.5 percent sensitivity at zero false certification rate (95% CI 96.2 to 99.4) with the constraint that no corrupted bundle receives certification. Sensitivity analysis showed witness count had the largest marginal effect, with three-witness arbitration providing 12 percentage points improvement over single-witness verification. Threshold modelling could enable context-specific TruthCert deployment where domains require different sensitivity-specificity trade-offs. The models were calibrated on synthetic data and recommendations may require recalibration for domain-specific scenarios with different corruption prevalence.
<!-- END-REWRITE -->

_Line range 21308-21383 in rewrite-workbook.txt_

---

## Entry 283 ([289/921]) — TSA

<details><summary>Metadata</summary>

```
TITLE: TSA Pro: World-First Browser-Based Trial Sequential Analysis with Alpha-Spending and Futility Boundaries
TYPE: methods  |  ESTIMAND: Cumulative Z-statistic relative to monitoring boundaries
DATA: Chronologically ordered meta-analysis data for sequential monitoring
PATH: C:\Models\TSA
```

</details>

### Original (frozen — do not edit)

```
Can trial sequential analysis with alpha-spending boundaries and futility rules be performed entirely in a browser to monitor accumulating meta-analytic evidence without requiring specialised desktop software? We developed TSA Pro as a 3,181-line single-file application implementing O Brien-Fleming, Pocock, and Haybittle-Peto alpha-spending functions with both binding and non-binding futility boundaries for cumulative meta-analysis monitoring. The tool computes required information size, constructs monitoring boundaries, plots cumulative Z-statistics against boundaries, and classifies the current evidence state as crossed, trending, in monitoring zone, or futile. Boundary calculations matched the TSA software and R rpact package within three decimal places across all validated scenarios including DAPA-HF, EMPEROR-Reduced, and corticosteroid exemplars. Futility boundary implementation correctly identified three simulated scenarios where early evidence suggested the treatment effect was unlikely to reach significance even with maximum planned information. Browser-based trial sequential analysis could democratise access to sequential monitoring methods for living meta-analysis teams without requiring software installation. The tool implements group-sequential boundaries and does not yet support adaptive information fraction designs or Bayesian monitoring approaches.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can trial sequential analysis with alpha-spending and futility boundaries be performed in a browser without specialised desktop software? We developed TSA Pro as a 3,181-line application implementing O Brien-Fleming, Pocock, and Haybittle-Peto alpha-spending functions with binding and non-binding futility boundaries for cumulative meta-analysis monitoring. The tool computes required information size, constructs monitoring boundaries, plots cumulative Z-statistics, and classifies evidence state as crossed, trending, monitoring, or futile. Boundary calculations matched TSA software and R rpact within three decimal places across all validated scenarios including DAPA-HF, EMPEROR-Reduced, and corticosteroid exemplars. Futility boundaries correctly identified three simulated scenarios where early evidence suggested treatment effect was unlikely to reach significance at maximum information. Browser-based trial sequential analysis could democratise sequential monitoring for living meta-analysis teams without software installation. The tool implements group-sequential boundaries and does not yet support adaptive information fraction designs or Bayesian monitoring.
<!-- END-REWRITE -->

_Line range 21384-21460 in rewrite-workbook.txt_

---

## Entry 284 ([290/921]) — waternajia

<details><summary>Metadata</summary>

```
TITLE: WaterNajia: A Bayesian Water Safety Risk Engine with Monte Carlo Simulation and Regional Bacteria Prevalence
TYPE: methods  |  ESTIMAND: Posterior risk probability with 95% credible interval
DATA: 15 risk factors, 6 water source types, WHO/UNICEF bacteria prevalence by world region
PATH: C:\Projects\waternajia
```

</details>

### Original (frozen — do not edit)

```
Can a browser-based Bayesian risk engine provide probabilistic water safety assessments calibrated to regional bacteria prevalence for low-resource settings? We built WaterNajia as a 1,784-line single-file application implementing logit-scale risk scoring with Monte Carlo simulation across 15 environmental and infrastructure risk factors for six water source types. The engine uses exponential decay modelling for time-since-contamination events, factor-group exclusivity logic, and region-specific bacteria prevalence priors derived from WHO and UNICEF surveillance data. For the full risk stack scenario with piped water, the posterior contamination probability was 0.92 (95% credible interval 0.87 to 0.96) from 200 Monte Carlo samples with seed-deterministic XorShift128Plus pseudorandom generation. A parallel Rust and WebAssembly implementation achieved bit-exact agreement with the JavaScript reference across all five golden test vectors. Real-time probabilistic water safety scoring could support field-level decision-making in humanitarian and public health contexts. The risk model relies on aggregate regional prevalence data and cannot capture hyperlocal contamination sources or seasonal variation.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a browser-based Bayesian risk engine provide probabilistic water safety assessments calibrated to regional bacteria prevalence? We implemented WaterNajia as a 1,784-line application with logit-scale risk scoring and Monte Carlo simulation across 15 environmental and infrastructure risk factors for six water source types. The engine models exponential decay for time-since-contamination events, factor-group exclusivity logic, and region-specific bacteria prevalence priors from WHO and UNICEF surveillance data. For the full risk stack scenario with piped water, the posterior contamination probability was 0.92 (95% credible interval 0.87 to 0.96) from 200 Monte Carlo samples with seed-deterministic pseudorandom generation. A parallel Rust and WebAssembly implementation achieved bit-exact agreement with the JavaScript reference across all five golden test vectors. Real-time probabilistic water safety scoring could support field-level decision-making in humanitarian and public health contexts. The risk model relies on aggregate regional prevalence data and cannot capture hyperlocal contamination sources.
<!-- END-REWRITE -->

_Line range 21461-21536 in rewrite-workbook.txt_

---

## Entry 285 ([291/921]) — AuthorshipLedger

<details><summary>Metadata</summary>

```
TITLE: AuthorshipLedger: DOI Deposit and Contributor Resolution for the C Drive Portfolio
TYPE: methods  |  ESTIMAND: proportion of indexed projects reaching full DOI-registrable state
DATA: See paper.json summary
PATH: C:\Users\user\AuthorshipLedger
```

</details>

### Original (frozen — do not edit)

```
Can public citation packets safely reach real DOI registration without resolving human metadata first? We reused bundled CitationWorkbench records and packet links for all 134 indexed projects. AuthorshipLedger v0.1 generated deposit drafts, ORCID intake templates, CRediT role templates, and SPDX-style license recommendations while separating institutional draft readiness from true registry readiness. High workflow readiness reached 64.2 percent (86 of 134 projects), and institutional draft readiness reached 50.7 percent (68 of 134), but fully registrable deposits remained 0.0 percent because no project yet preserved named human creators, ORCID identifiers, confirmed CRediT roles, or asserted final licenses. Journal targets were preserved for only 4.5 percent of records, making authorship and governance, not DataCite core fields, the true next bottleneck. This turns the next portfolio task into contributor and licensing resolution rather than further metadata generation. The ledger clarifies the queue, but it still relies on heuristic role templates, institutional fallback creators, and cannot authorize DOI registration by itself.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can public citation packets safely reach real DOI registration without resolving human metadata first? We reused bundled CitationWorkbench records and packet links for all 134 indexed projects. AuthorshipLedger v0.1 generated deposit drafts, ORCID intake templates, CRediT role templates, and SPDX-style license recommendations while separating institutional draft readiness from true registry readiness. High workflow readiness reached 64.2 percent (86 of 134 projects), and institutional draft readiness reached 50.7 percent (68 of 134), but fully registrable deposits remained 0.0 percent because no project yet preserved named human creators, ORCID identifiers, confirmed CRediT roles, or asserted final licenses. Journal targets were preserved for only 4.5 percent of records, making authorship and governance, not DataCite core fields, the true next bottleneck. This turns the next portfolio task into contributor and licensing resolution rather than further metadata generation. The ledger clarifies the queue, but it still relies on heuristic role templates, institutional fallback creators, and cannot authorize DOI registration by itself.
<!-- END-REWRITE -->

_Line range 21537-21611 in rewrite-workbook.txt_

---

## Entry 286 ([292/921]) — CitationWorkbench

<details><summary>Metadata</summary>

```
TITLE: CitationWorkbench: Citation Packet Generation for the C Drive Portfolio
TYPE: methods  |  ESTIMAND: proportion of indexed projects reaching high citation readiness
DATA: See paper.json summary
PATH: C:\Users\user\CitationWorkbench
```

</details>

### Original (frozen — do not edit)

```
Can an internal research portfolio be converted into citation packets and DOI-facing metadata without hand-writing records one by one? We reused bundled PortfolioCatalog records, which exposed public landing pages for 134 indexed projects. CitationWorkbench v0.1 generated CFF, DataCite draft JSON, CiteProc JSON, and BibTeX for every project while scoring citation readiness from lifecycle, release, journal, and manuscript signals. High citation readiness reached 64.2 percent (86 of 134 projects), release-ready citation packets reached 50.7 percent (68 of 134), and DataCite core fields were derivable for all 134 records. Paper-backed coverage reached 68.7 percent, but only 4.5 percent preserved a target journal, making journal metadata the dominant citation gap rather than missing titles or URLs. This shifts the next portfolio task toward preserving venue targets, licensing, and authorship decisions instead of inventing more metadata shells. The packet factory improves citation hygiene, but it still produces draft metadata, does not register DOIs, and cannot prove authorship for collaborative work.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can an internal research portfolio be converted into citation packets and DOI-facing metadata without hand-writing records one by one? We reused bundled PortfolioCatalog records, which exposed public landing pages for 134 indexed projects. CitationWorkbench v0.1 generated CFF, DataCite draft JSON, CiteProc JSON, and BibTeX for every project while scoring citation readiness from lifecycle, release, journal, and manuscript signals. High citation readiness reached 64.2 percent (86 of 134 projects), release-ready citation packets reached 50.7 percent (68 of 134), and DataCite core fields were derivable for all 134 records. Paper-backed coverage reached 68.7 percent, but only 4.5 percent preserved a target journal, making journal metadata the dominant citation gap rather than missing titles or URLs. This shifts the next portfolio task toward preserving venue targets, licensing, and authorship decisions instead of inventing more metadata shells. The packet factory improves citation hygiene, but it still produces draft metadata, does not register DOIs, and cannot prove authorship for collaborative work.
<!-- END-REWRITE -->

_Line range 21612-21686 in rewrite-workbook.txt_

---

## Entry 287 ([293/921]) — DrivePulse

<details><summary>Metadata</summary>

```
TITLE: DrivePulse: Live Folder Telemetry for the C Drive Evidence Portfolio
TYPE: methods  |  ESTIMAND: proportion of specific indexed paths exposing git repositories
DATA: See paper.json summary
PATH: C:\Users\user\DrivePulse
```

</details>

### Original (frozen — do not edit)

```
Can the portfolio atlas be linked back to live folder evidence rather than relying on index rows? We reused the bundled ResearchConstellation snapshot, deduplicated its 134 project records into 107 indexed paths, and refreshed those paths against the current C drive. DrivePulse v0.1 captured existence, recency, git state, README markers, test markers, paper artifacts, protocol artifacts, and Pages signals into a telemetry snapshot. All 105 specific filesystem paths were found live, and 85.7 percent (90 of 105) exposed git repositories while 79.0 percent (83 of 105) were already Pages-ready. Signal density peaked in tiers 4 and 7, whereas tier 12 collapsed to a generic root path and tier 8 remained operationally sparse. This shifts the next portfolio task from directory discovery toward index cleanup and evidence normalization, because the folders now exist but the metadata layer remains uneven. The scan improves operational visibility, but it is shallow, machine-specific, and cannot replace deeper repository or manuscript audits.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can the portfolio atlas be linked back to live folder evidence rather than relying on index rows? We reused the bundled ResearchConstellation snapshot, deduplicated its 134 project records into 107 indexed paths, and refreshed those paths against the current C drive. DrivePulse v0.1 captured existence, recency, git state, README markers, test markers, paper artifacts, protocol artifacts, and Pages signals into a telemetry snapshot. All 105 specific filesystem paths were found live, and 85.7 percent (90 of 105) exposed git repositories while 79.0 percent (83 of 105) were already Pages-ready. Signal density peaked in tiers 4 and 7, whereas tier 12 collapsed to a generic root path and tier 8 remained operationally sparse. This shifts the next portfolio task from directory discovery toward index cleanup and evidence normalization, because the folders now exist but the metadata layer remains uneven. The scan improves operational visibility, but it is shallow, machine-specific, and cannot replace deeper repository or manuscript audits.
<!-- END-REWRITE -->

_Line range 21687-21761 in rewrite-workbook.txt_

---

## Entry 288 ([294/921]) — EvidenceBridgeFHIR

<details><summary>Metadata</summary>

```
TITLE: EvidenceBridgeFHIR: Exporting the C Drive Evidence Portfolio into Citation and ArtifactAssessment Bundles
TYPE: methods  |  ESTIMAND: ArtifactAssessment coverage across exported projects
DATA: See paper.json summary
PATH: C:\Users\user\EvidenceBridgeFHIR
```

</details>

### Original (frozen — do not edit)

```
Can a heterogeneous C-drive methods portfolio be exported into a standards-facing exchange format without losing its operational status signals? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and mapped each project into a FHIR Citation record. EvidenceBridgeFHIR v0.1 then attached ArtifactAssessment resources only where the source snapshot already carried an explicit lifecycle label suitable for reuse. The resulting bundle contained 185 FHIR resources, combining 134 Citations with 51 ArtifactAssessments for 38.1 percent coverage (51 of 134), while 83 projects remained citation-only placeholders. Citation-only pressure clustered in tiers 10 and 12, which supplied 57 unresolved exports and dominated the interoperability backlog to date despite the portfolio's broader methodological depth. This shows the next barrier is not exchange syntax but portfolio curation, because standards layers cannot recover lifecycle judgments that were never frozen upstream. The bundle improves inspectability, but it does not validate against a live FHIR server or infer missing assessments automatically.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a heterogeneous C-drive methods portfolio be exported into a standards-facing exchange format without losing its operational status signals? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and mapped each project into a FHIR Citation record. EvidenceBridgeFHIR v0.1 then attached ArtifactAssessment resources only where the source snapshot already carried an explicit lifecycle label suitable for reuse. The resulting bundle contained 185 FHIR resources, combining 134 Citations with 51 ArtifactAssessments for 38.1 percent coverage (51 of 134), while 83 projects remained citation-only placeholders. Citation-only pressure clustered in tiers 10 and 12, which supplied 57 unresolved exports and dominated the interoperability backlog to date despite the portfolio's broader methodological depth. This shows the next barrier is not exchange syntax but portfolio curation, because standards layers cannot recover lifecycle judgments that were never frozen upstream. The bundle improves inspectability, but it does not validate against a live FHIR server or infer missing assessments automatically.
<!-- END-REWRITE -->

_Line range 21762-21836 in rewrite-workbook.txt_

---

## Entry 289 ([295/921]) — EvidenceCrate

<details><summary>Metadata</summary>

```
TITLE: EvidenceCrate: Packaging the C Drive Research Portfolio as a Static Metadata Crate
TYPE: methods  |  ESTIMAND: explicit lifecycle coverage in packaged entities
DATA: See paper.json summary
PATH: C:\Users\user\EvidenceCrate
```

</details>

### Original (frozen — do not edit)

```
Can a portfolio atlas become a research package rather than a browser view of scattered projects? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and preserved its status normalization outputs. EvidenceCrate v0.1 transforms that snapshot into dashboard data, a CodeMeta record, and an RO-Crate style metadata graph with tier and project entities. The generated crate contained 156 graph nodes and preserved explicit lifecycle coverage for 38.1 percent of projects (51 of 134), leaving 83 records as metadata-ready but status-incomplete entities. Tier collections exposed a sharp divide: tiers 2, 3, 4, and 7 exported cleanly, whereas tiers 6, 8, 10, and 12 remained dominated by unresolved rows. This shifts the next portfolio task from interface design toward packaging discipline, because metadata standards only help once project states are frozen upstream. The crate improves portability and reuse, but it does not validate RO-Crate profiles, inspect live folders, or repair ambiguous source labels automatically.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a portfolio atlas become a research package rather than a browser view of scattered projects? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and preserved its status normalization outputs. EvidenceCrate v0.1 transforms that snapshot into dashboard data, a CodeMeta record, and an RO-Crate style metadata graph with tier and project entities. The generated crate contained 156 graph nodes and preserved explicit lifecycle coverage for 38.1 percent of projects (51 of 134), leaving 83 records as metadata-ready but status-incomplete entities. Tier collections exposed a sharp divide: tiers 2, 3, 4, and 7 exported cleanly, whereas tiers 6, 8, 10, and 12 remained dominated by unresolved rows. This shifts the next portfolio task from interface design toward packaging discipline, because metadata standards only help once project states are frozen upstream. The crate improves portability and reuse, but it does not validate RO-Crate profiles, inspect live folders, or repair ambiguous source labels automatically.
<!-- END-REWRITE -->

_Line range 21837-21911 in rewrite-workbook.txt_

---

## Entry 290 ([296/921]) — FAIRPortfolio

<details><summary>Metadata</summary>

```
TITLE: FAIRPortfolio: Proxy Maturity Scoring for the C Drive Evidence Portfolio
TYPE: methods  |  ESTIMAND: proportion of projects scoring at least 70/100 on the FAIR-style proxy scale
DATA: See paper.json summary
PATH: C:\Users\user\FAIRPortfolio
```

</details>

### Original (frozen — do not edit)

```
Can a C-drive portfolio be prioritised with FAIR-style signals even when the snapshot is too thin for FAIR assessment? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and scored each record on findable, accessible, interoperable, and reusable proxy components. FAIRPortfolio v0.1 assigns a 100-point total by combining path specificity, delivery signals, automation cues, lifecycle normalization, and maturity evidence such as tests, versions, or manuscripts. Mean proxy maturity reached 48.6 points, and only 14.2 percent of projects (19 of 134) scored at least 70/100, while 35.1 percent (47 of 134) remained below 40. Stronger scores concentrated in tiers 2 and 1, whereas tier 12 had the lowest average score and tier 9 remained structurally weak. This suggests the next gain comes from metadata discipline and public delivery signals rather than inventing another analysis engine. The dashboard improves prioritisation, but it is only a FAIR-inspired proxy and cannot substitute for standards-grade compliance assessment.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a C-drive portfolio be prioritised with FAIR-style signals even when the snapshot is too thin for FAIR assessment? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and scored each record on findable, accessible, interoperable, and reusable proxy components. FAIRPortfolio v0.1 assigns a 100-point total by combining path specificity, delivery signals, automation cues, lifecycle normalization, and maturity evidence such as tests, versions, or manuscripts. Mean proxy maturity reached 48.6 points, and only 14.2 percent of projects (19 of 134) scored at least 70/100, while 35.1 percent (47 of 134) remained below 40. Stronger scores concentrated in tiers 2 and 1, whereas tier 12 had the lowest average score and tier 9 remained structurally weak. This suggests the next gain comes from metadata discipline and public delivery signals rather than inventing another analysis engine. The dashboard improves prioritisation, but it is only a FAIR-inspired proxy and cannot substitute for standards-grade compliance assessment.
<!-- END-REWRITE -->

_Line range 21912-21986 in rewrite-workbook.txt_

---

## Entry 291 ([297/921]) — PortfolioCatalog

<details><summary>Metadata</summary>

```
TITLE: PortfolioCatalog: Public Discovery Layer for the C Drive Portfolio
TYPE: methods  |  ESTIMAND: proportion of indexed projects reaching high discoverability coverage
DATA: See paper.json summary
PATH: C:\Users\user\PortfolioCatalog
```

</details>

### Original (frozen — do not edit)

```
Can a fragmented C-drive research portfolio be converted into a public discovery layer rather than remaining an internal index? We reused bundled snapshots from ResearchConstellation, DrivePulse, PortfolioOps, and FAIRPortfolio, covering 134 indexed projects. PortfolioCatalog v0.1 generated one static landing page per project plus DCAT 3, Schema.org, and sitemap exports for GitHub Pages delivery in this release. High discoverability coverage reached 56.7 percent (76 of 134 projects), while 50.7 percent (68 of 134) met the stricter strong-public-record criterion combining resolved status, public Pages signal, and discoverability score of at least 70/100. Resolved lifecycle coverage remained 61.9 percent, evidence-rich records reached 66.4 percent, and Tier 12 still collapsed to a mean discoverability score of 6.7. This shifts the next portfolio task toward metadata repair, public delivery, and lifecycle decisions instead of building yet another internal dashboard. The catalog improves external visibility, but it inherits heuristic weighting, snapshot lag, and does not prove that discoverable work is scientifically mature.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a fragmented C-drive research portfolio be converted into a public discovery layer rather than remaining an internal index? We reused bundled snapshots from ResearchConstellation, DrivePulse, PortfolioOps, and FAIRPortfolio, covering 134 indexed projects. PortfolioCatalog v0.1 generated one static landing page per project plus DCAT 3, Schema.org, and sitemap exports for GitHub Pages delivery in this release. High discoverability coverage reached 56.7 percent (76 of 134 projects), while 50.7 percent (68 of 134) met the stricter strong-public-record criterion combining resolved status, public Pages signal, and discoverability score of at least 70/100. Resolved lifecycle coverage remained 61.9 percent, evidence-rich records reached 66.4 percent, and Tier 12 still collapsed to a mean discoverability score of 6.7. This shifts the next portfolio task toward metadata repair, public delivery, and lifecycle decisions instead of building yet another internal dashboard. The catalog improves external visibility, but it inherits heuristic weighting, snapshot lag, and does not prove that discoverable work is scientifically mature.
<!-- END-REWRITE -->

_Line range 21987-22061 in rewrite-workbook.txt_

---

## Entry 292 ([298/921]) — PortfolioOps

<details><summary>Metadata</summary>

```
TITLE: PortfolioOps: Operational Fusion for the C Drive Evidence Portfolio
TYPE: methods  |  ESTIMAND: proportion of projects classified as operationally backed
DATA: See paper.json summary
PATH: C:\Users\user\PortfolioOps
```

</details>

### Original (frozen — do not edit)

```
Can portfolio layers be fused into one operational view rather than read one tool at a time? We reused bundled snapshots from ResearchConstellation, DrivePulse, TriageWorkbench, and FAIRPortfolio, covering 134 indexed projects. PortfolioOps v0.1 merged explicit status labels, medium-or-high confidence triage suggestions, live folder telemetry, publish signals, code signals, and FAIR-style maturity into one readiness model. Only 23.1 percent of projects (31 of 134) were currently operationally backed, while 55.2 percent (74 of 134) reached readiness scores of at least 70/100. Triage suggestions resolved 32 additional statuses, lifting total resolved rows to 83 of 134, but Tier 12 still collapsed under generic root indexing and the weakest mean readiness. This turns the next portfolio task into operational cleanup rather than another app, because the merged evidence now shows where status, packaging, and delivery still break together. The cockpit improves coordination, but it inherits snapshot lag and cannot guarantee that a high readiness score reflects real scientific quality.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can portfolio layers be fused into one operational view rather than read one tool at a time? We reused bundled snapshots from ResearchConstellation, DrivePulse, TriageWorkbench, and FAIRPortfolio, covering 134 indexed projects. PortfolioOps v0.1 merged explicit status labels, medium-or-high confidence triage suggestions, live folder telemetry, publish signals, code signals, and FAIR-style maturity into one readiness model. Only 23.1 percent of projects (31 of 134) were currently operationally backed, while 55.2 percent (74 of 134) reached readiness scores of at least 70/100. Triage suggestions resolved 32 additional statuses, lifting total resolved rows to 83 of 134, but Tier 12 still collapsed under generic root indexing and the weakest mean readiness. This turns the next portfolio task into operational cleanup rather than another app, because the merged evidence now shows where status, packaging, and delivery still break together. The cockpit improves coordination, but it inherits snapshot lag and cannot guarantee that a high readiness score reflects real scientific quality.
<!-- END-REWRITE -->

_Line range 22062-22136 in rewrite-workbook.txt_

---

## Entry 293 ([299/921]) — ProvenanceAtlas

<details><summary>Metadata</summary>

```
TITLE: ProvenanceAtlas: Static Lineage Graphing for the C Drive Evidence Portfolio
TYPE: methods  |  ESTIMAND: explicit lifecycle coverage in the provenance graph
DATA: See paper.json summary
PATH: C:\Users\user\ProvenanceAtlas
```

</details>

### Original (frozen — do not edit)

```
Can a portfolio inventory also show how its evidence was transformed, not just what projects it contains? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and converted it into a PROV-style entity-activity-agent graph. ProvenanceAtlas v0.1 emits project entities, tier entities, summary outputs, and explicit build activities so lineage remains inspectable in a static repository for downstream review. The generated graph contained 157 nodes and 439 edges, while explicit lifecycle coverage remained 38.1 percent (51 of 134 projects), leaving 83 unresolved records inside the lineage. The strongest provenance pressure came from tiers 10 and 12, which alone contributed 57 unresolved projects and concentrated most broken downstream status chains. This reframes the portfolio gap as a provenance problem: without frozen lifecycle labels, later packaging, dashboards, and exchange layers inherit ambiguity by design. The atlas clarifies derivation paths, but it does not inspect live filesystem events, Git history, or authorship beyond the bundled snapshot.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a portfolio inventory also show how its evidence was transformed, not just what projects it contains? We reused the bundled ResearchConstellation snapshot containing 134 indexed projects across 12 tiers and converted it into a PROV-style entity-activity-agent graph. ProvenanceAtlas v0.1 emits project entities, tier entities, summary outputs, and explicit build activities so lineage remains inspectable in a static repository for downstream review. The generated graph contained 157 nodes and 439 edges, while explicit lifecycle coverage remained 38.1 percent (51 of 134 projects), leaving 83 unresolved records inside the lineage. The strongest provenance pressure came from tiers 10 and 12, which alone contributed 57 unresolved projects and concentrated most broken downstream status chains. This reframes the portfolio gap as a provenance problem: without frozen lifecycle labels, later packaging, dashboards, and exchange layers inherit ambiguity by design. The atlas clarifies derivation paths, but it does not inspect live filesystem events, Git history, or authorship beyond the bundled snapshot.
<!-- END-REWRITE -->

_Line range 22137-22211 in rewrite-workbook.txt_

---

## Entry 294 ([300/921]) — ResearchConstellation

<details><summary>Metadata</summary>

```
TITLE: Research Constellation: A Live Portfolio Status Atlas for the C Drive Evidence Stack
TYPE: methods  |  ESTIMAND: explicit status coverage
DATA: See paper.json summary
PATH: C:\Users\user\ResearchConstellation
```

</details>

### Original (frozen — do not edit)

```
Can a portfolio layer expose where an evidence-synthesis estate is organized well enough to operate, and where it still lacks status control? We parsed a bundled ProjectIndex snapshot, covering 134 projects across 12 tiers spanning flagship tools, HTML apps, HTA systems, datasets, courses, and exploratory research. Research Constellation v0.1 compiles that registry into cards, tier summaries, status filters, and a needs-triage queue without adding an analysis engine. Across the index, only 38.1 percent of projects (51 of 134) carried status labels, leaving 83 records unlabeled and Tier 10 alone contributing 32 triage rows. Submission-ready work concentrated in tiers 3, 4, 5, and 7, whereas infrastructure, educational, and backlog tiers showed zero explicit coverage. This makes the portfolio gap operational rather than methodological: status normalization now matters more than inventing another app family. The atlas improves visibility, but it depends on the snapshot remaining current, and it does not yet merge metadata, validation artifacts, or Git state.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can a portfolio layer expose where an evidence-synthesis estate is organized well enough to operate, and where it still lacks status control? We parsed a bundled ProjectIndex snapshot, covering 134 projects across 12 tiers spanning flagship tools, HTML apps, HTA systems, datasets, courses, and exploratory research. Research Constellation v0.1 compiles that registry into cards, tier summaries, status filters, and a needs-triage queue without adding an analysis engine. Across the index, only 38.1 percent of projects (51 of 134) carried status labels, leaving 83 records unlabeled and Tier 10 alone contributing 32 triage rows. Submission-ready work concentrated in tiers 3, 4, 5, and 7, whereas infrastructure, educational, and backlog tiers showed zero explicit coverage. This makes the portfolio gap operational rather than methodological: status normalization now matters more than inventing another app family. The atlas improves visibility, but it depends on the snapshot remaining current, and it does not yet merge metadata, validation artifacts, or Git state.
<!-- END-REWRITE -->

_Line range 22212-22286 in rewrite-workbook.txt_

---

## Entry 295 ([301/921]) — SubmissionCockpit

<details><summary>Metadata</summary>

```
TITLE: SubmissionCockpit: Editorial Release Control for the C Drive Research Portfolio
TYPE: methods  |  ESTIMAND: proportion of indexed projects currently carrying resolved submission-ready status
DATA: See paper.json summary
PATH: C:\Users\user\SubmissionCockpit
```

</details>

### Original (frozen — do not edit)

```
Can one tracker govern rewriting and publication across a fast-growing E156 portfolio without spreadsheet drift? SubmissionCockpit merged current outputs from ResearchConstellation, PortfolioOps, CitationWorkbench, and AuthorshipLedger across 466 tracked projects and synchronized them with the canonical rewrite workbook. The refreshed ledger marked 430 projects as publish-now candidates, 426 with workbook rewrites present, 191 with body-ready status, 122 with code-release readiness, and 114 ready for Pages publication. Only 26 projects currently carried resolved submission-ready status, while zero were cleanly ready for immediate GitHub sync because rewrite validation, license assertion, or release wiring still lagged. Deterministic rebuilds now derive top-level timestamps from source mtimes, preserve stable JSON and JS line endings, and avoid needless workbook rewrites when tracker rows are unchanged. This turns the publication problem into explicit queue repair rather than snapshot debugging, because build noise no longer masks blockers. The limitation is that cockpit review remains manual, and ledger quality still depends on upstream portfolio metadata being current.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can one tracker govern rewriting and publication of a multi-project E156 portfolio across GitHub and Pages? We fused current outputs from ResearchConstellation, PortfolioOps, CitationWorkbench, and AuthorshipLedger across 134 indexed projects and generated a canonical rewrite workbook for editorial tracking. SubmissionCockpit syncs portfolio metadata, manual rewrite states, MIT-license intent, GitHub and Pages delivery flags, and future Synthesis Journal upload placeholders into one publication ledger. Across 134 indexed projects, 26 carried resolved submission-ready status, a portfolio submission proportion of 19.4 percent (95% CI 12.7-26.1). Another 68 projects already had citation-readiness scores of at least 90, and 134 had draft deposit manifests available for reuse, plus public packet links, queue pages, and license recommendations. This turns the publication problem into queue management, because the remaining gaps now become explicit blockers for rewrite, packaging, release, and upload. The limitation is that cockpit review remains manual, and PDF galley upload will stay pending until journal credentials and article files are available.
<!-- END-REWRITE -->

_Line range 22287-22361 in rewrite-workbook.txt_

---

## Entry 296 ([302/921]) — TriageWorkbench

<details><summary>Metadata</summary>

```
TITLE: TriageWorkbench: Rule-Based Lifecycle Freezing for the Unresolved Portfolio Queue
TYPE: methods  |  ESTIMAND: non-triage recommendation coverage across unresolved rows
DATA: See paper.json summary
PATH: C:\Users\user\TriageWorkbench
```

</details>

### Original (frozen — do not edit)

```
Can the portfolio's unresolved queue be reduced before more dashboards inherit the same ambiguity today? We reused the bundled ResearchConstellation snapshot and isolated 83 projects currently lacking explicit status labels across the 134-project portfolio. TriageWorkbench v0.1 applied deterministic rules to each unresolved row, weighting tests, manuscript, dashboard, review clean, and generic root paths to suggest a lifecycle label and confidence tier. The workbench produced non-triage recommendations for 65.1 percent of unresolved rows (54 of 83), leaving 29 unreduced and only 42.2 percent (35 of 83) reaching medium-or-high confidence. Recommendation pressure centered in tiers 10 and 12, which supplied 57 of 83 unresolved inputs, while active-like suggestions still dominated the generated label mix. This makes the next portfolio step a curation workflow problem, because deterministic triage can substantially shrink the queue before manual review begins. The workbench improves prioritization, but it does not inspect folders, confirm git state, or guarantee that its rule-based labels are consistently correct.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can the portfolio's unresolved queue be reduced before more dashboards inherit the same ambiguity today? We reused the bundled ResearchConstellation snapshot and isolated 83 projects currently lacking explicit status labels across the 134-project portfolio. TriageWorkbench v0.1 applied deterministic rules to each unresolved row, weighting tests, manuscript, dashboard, review clean, and generic root paths to suggest a lifecycle label and confidence tier. The workbench produced non-triage recommendations for 65.1 percent of unresolved rows (54 of 83), leaving 29 unreduced and only 42.2 percent (35 of 83) reaching medium-or-high confidence. Recommendation pressure centered in tiers 10 and 12, which supplied 57 of 83 unresolved inputs, while active-like suggestions still dominated the generated label mix. This makes the next portfolio step a curation workflow problem, because deterministic triage can substantially shrink the queue before manual review begins. The workbench improves prioritization, but it does not inspect folders, confirm git state, or guarantee that its rule-based labels are consistently correct.
<!-- END-REWRITE -->

_Line range 22362-22436 in rewrite-workbook.txt_

---

## Entry 297 ([303/921]) — ActionableEvidence

<details><summary>Metadata</summary>

```
TITLE: ActionableEvidence: GO/NO-GO Verdicts for Cochrane Meta-Analyses Using Six-Criterion Actionability
TYPE: methods  |  ESTIMAND: Actionability classification (GO/CAUTION/NO-GO)
DATA: Pairwise70 Cochrane meta-analysis recomputations
PATH: C:\Models\ActionableEvidence
```

</details>

### Original (frozen — do not edit)

```
What fraction of Cochrane pairwise meta-analyses produce evidence actionable enough for a GO clinical verdict under a multi-criterion framework? We built a 983-line dashboard that recomputes each Pairwise70 meta-analysis and applies six actionability criteria: statistical significance, prediction interval direction, GRADE certainty, fragility index threshold, heterogeneity acceptability, and small-study effect absence. Each review receives a composite GO, CAUTION, or NO-GO verdict based on how many criteria are satisfied, with configurable thresholds allowing users to adjust stringency per domain. Only 1.3 percent of reviews achieved a full GO verdict across all six criteria (95% CI 0.4 to 2.9), while 48 percent met fewer than three criteria and received NO-GO classifications. The most common failure modes were inadequate fragility index and prediction intervals crossing the null, rather than statistical non-significance alone. Multi-criterion actionability assessment reveals that most Cochrane conclusions lack the robustness profile needed for confident clinical action. The framework applies heuristic thresholds that have not been calibrated against real-world clinical decision outcomes.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
What fraction of Cochrane meta-analyses produce evidence actionable enough for a GO clinical verdict under a multi-criterion framework? We built a 983-line dashboard recomputing each Pairwise70 meta-analysis and applying six criteria: significance, prediction interval direction, GRADE certainty, fragility threshold, heterogeneity, and small-study effect absence. Each review receives GO, CAUTION, or NO-GO based on how many criteria are satisfied with configurable stringency thresholds. Only 1.3 percent of reviews achieved full GO across all six criteria (95% CI 0.4 to 2.9), while 48 percent met fewer than three and received NO-GO. The most common failure modes were inadequate fragility index and prediction intervals crossing the null, rather than non-significance alone. Multi-criterion actionability assessment reveals that most Cochrane conclusions lack the robustness profile for confident clinical action. The framework applies heuristic thresholds not calibrated against real-world clinical decision outcomes.
<!-- END-REWRITE -->

_Line range 22437-22511 in rewrite-workbook.txt_

---

## Entry 298 ([304/921]) — AutoReview

<details><summary>Metadata</summary>

```
TITLE: AutoReview: Automated Systematic Review Quality Assessment from Manuscript Text
TYPE: methods  |  ESTIMAND: Reporting quality score and AMSTAR-2 compliance rate
DATA: Systematic review manuscripts for automated quality assessment
PATH: C:\Models\AutoReview
```

</details>

### Original (frozen — do not edit)

```
Can automated text analysis of systematic review manuscripts produce AMSTAR-2 quality assessments concordant with expert evaluation? We developed AutoReview implementing natural language processing classifiers for each of the 16 AMSTAR-2 critical and non-critical domains, trained on manually assessed review manuscripts with confirmed domain ratings. The tool parses manuscript sections, identifies reporting elements relevant to each AMSTAR-2 item, and generates domain-level compliance ratings of yes, partial yes, or no with supporting text excerpts. Automated assessments achieved 84 percent agreement (95% CI 79 to 89) with expert AMSTAR-2 ratings across validation manuscripts, with highest accuracy for protocol registration and search strategy reporting domains. Discrepancies concentrated in domains requiring subjective judgment such as adequacy of risk-of-bias assessment and appropriateness of meta-analytic methods. Automated quality assessment could provide rapid preliminary screening of systematic review quality for evidence surveillance and guideline development. The tool assesses reporting completeness and cannot evaluate whether the reported methods were correctly implemented or whether the interpretation is appropriate.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can automated text analysis of systematic review manuscripts produce AMSTAR-2 assessments concordant with expert evaluation? We developed AutoReview implementing NLP classifiers for each of the 16 AMSTAR-2 domains, trained on manually assessed review manuscripts with confirmed ratings. The tool parses manuscript sections, identifies reporting elements for each item, and generates domain ratings of yes, partial yes, or no with supporting text excerpts. Automated assessments achieved 84 percent agreement (95% CI 79 to 89) with expert AMSTAR-2 ratings across validation manuscripts. Discrepancies concentrated in domains requiring subjective judgment such as adequacy of risk-of-bias assessment and meta-analytic method appropriateness. Automated quality assessment could provide rapid preliminary screening for evidence surveillance and guideline development. The tool assesses reporting completeness and cannot evaluate whether methods were correctly implemented.
<!-- END-REWRITE -->

_Line range 22512-22586 in rewrite-workbook.txt_

---

## Entry 299 ([305/921]) — ContradictionMap

<details><summary>Metadata</summary>

```
TITLE: ContradictionMap: Detecting Where Cochrane Evidence Contradicts Itself Across Shared Primary Studies
TYPE: methods  |  ESTIMAND: Contradiction rate across overlapping reviews
DATA: Pairwise70 corpus with cross-review overlap detection
PATH: C:\Models\ContradictionMap
```

</details>

### Original (frozen — do not edit)

```
How often do Cochrane meta-analyses that share primary studies reach contradictory conclusions, and what drives these discrepancies? ContradictionMap recomputes meta-analyses from the Pairwise70 corpus, detects cross-review study overlap, and classifies pairs as concordant, discordant, or contradictory based on effect direction and statistical significance agreement. The pipeline builds a network of shared studies across 501 reviews and applies pairwise contradiction scoring to overlapping review pairs. Of 1,247 overlapping review pairs, 48.9 percent showed contradictory conclusions (95% CI 46.1 to 51.7) where the same primary studies contributed to opposing pooled verdicts. Contradictions were driven primarily by differences in study inclusion criteria and effect measure choice rather than statistical method selection. The high contradiction rate suggests that systematic review conclusions are more sensitive to review-level methodological choices than commonly appreciated. The analysis cannot determine which contradicting review is correct, only that the same evidence base supports opposing conclusions under different analytical frameworks.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
How often do Cochrane meta-analyses sharing primary studies reach contradictory conclusions? ContradictionMap recomputes meta-analyses from the Pairwise70 corpus, detects cross-review study overlap, and classifies pairs as concordant, discordant, or contradictory based on effect direction and significance agreement. The pipeline builds a network of shared studies across 501 reviews and applies pairwise contradiction scoring to overlapping pairs. Of 1,247 overlapping pairs, 48.9 percent showed contradictory conclusions (95% CI 46.1 to 51.7) where the same primary studies contributed to opposing verdicts. Contradictions were driven primarily by differences in inclusion criteria and effect measure choice rather than statistical method selection. The high contradiction rate suggests systematic review conclusions are more sensitive to methodological choices than commonly appreciated. The analysis cannot determine which review is correct, only that the same evidence supports opposing conclusions under different frameworks.
<!-- END-REWRITE -->

_Line range 22587-22661 in rewrite-workbook.txt_

---

## Entry 300 ([306/921]) — EquityMA

<details><summary>Metadata</summary>

```
TITLE: EquityMA: PROGRESS-Plus Equity-Stratified Meta-Analysis Tool
TYPE: methods  |  ESTIMAND: Equity-stratified pooled effect with subgroup interaction test
DATA: Meta-analysis data stratified by PROGRESS-Plus equity dimensions
PATH: C:\Models\EquityMA
```

</details>

### Original (frozen — do not edit)

```
Can equity-stratified meta-analysis quantify differential treatment effects across PROGRESS-Plus dimensions to identify health inequities hidden in overall pooled estimates? We built EquityMA as a 1,774-line browser application implementing subgroup meta-analysis stratified by place, race, occupation, gender, religion, education, socioeconomic status, and social capital with interaction tests for equity modification. The tool computes within-stratum pooled effects, between-stratum heterogeneity, and ratio of relative risks to quantify the magnitude of equity-related effect modification. Across test datasets the equity interaction test correctly identified simulated differential effects with power of 0.82 (95% CI 0.76 to 0.88) when the true stratum-specific effects differed by more than 30 percent. Equity gap visualisation showed that overall pooled estimates masked clinically important between-group differences in three of five test scenarios. Stratified meta-analysis across equity dimensions could support health policy decisions aimed at reducing treatment access and outcome disparities. The analysis requires studies to report equity-stratified outcomes, which are available in fewer than 20 percent of published trials.
```

### YOUR REWRITE

<!-- BEGIN-REWRITE -->
Can equity-stratified meta-analysis quantify differential treatment effects across PROGRESS-Plus dimensions to identify hidden health inequities? We built EquityMA as a 1,774-line browser application implementing subgroup meta-analysis stratified by place, race, occupation, gender, religion, education, socioeconomic status, and social capital with interaction tests. The tool computes within-stratum effects, between-stratum heterogeneity, and ratio of relative risks to quantify equity-related effect modification. The equity interaction test correctly identified simulated differential effects with power of 0.82 (95% CI 0.76 to 0.88) when stratum-specific effects differed by more than 30 percent. Equity gap visualisation showed overall pooled estimates masked clinically important between-group differences in three of five test scenarios. Stratified analysis across equity dimensions could support policy decisions aimed at reducing treatment access and outcome disparities. The analysis requires equity-stratified outcomes available in fewer than 20 percent of published trials.
<!-- END-REWRITE -->

_Line range 22662-22736 in rewrite-workbook.txt_

---

